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Background: There is paucity of evidence to guide case-finding strategies in field trials of 
new tuberculosis vaccines conducted in young children.  
Aim: To investigate case-finding and case detection methods for tuberculosis in tuberculosis 
field trials conducted in young children.  
Methods: Age-specific tuberculosis incidence was calculated among children less than 5 
years old. In a second study, Bacille Calmette-Guérin vaccinated infants were randomised to 
tuberculosis case finding through regular home visits and record surveillance (Group 1) or 
record surveillance only (Group 2), and followed up for at least 2 years. TB suspects were 
evaluated for tuberculosis using standardized tests including chest radiographs. A sample of 
children was also tested using the QuantiFERON TB-Gold-In-Tube assay. Hospital 
admission and mortality data in children enrolled in two tuberculosis vaccine studies were 
analysed.  
Results: The incidence of tuberculosis peaked at a rate of 1.21% in the 12-23 month age 
group, with rates remaining high beyond 24 months (1% in the 24-35 month age group). The 
case-finding rate was significantly greater in Group 1 case-finding:-2.2/100 py compared to:-
0.8/100 py in Group 2 case-finding; case-finding rate ratio 2.6 (95%CI 1.8–4.0, p < 0.001). 
Agreement between the tuberculin skin test and the QuantiFERON assay was excellent (94%, 
κ =0.79, 95%CI 0.69–0.89). Isolated hilar lymphadenopathy and parenchymal consolidation 
were the most frequent chest radiographic findings in children with suspected tuberculosis. 
TB accounted for 4% and 0.3%, and 6% and 1% of admissions and deaths respectively in the 
two tuberculosis vaccine studies analysed. 
Conclusions: Infant tuberculosis vaccine trials can increase case accrual by extending 
participant follow-up beyond 24 months. Tuberculosis case finding that incorporates regular 
home visits maximises case detection, yielding more cases than record surveillance with a 
study close-out visit. The tuberculin skin test remains a useful diagnostic aid for tuberculosis 
in young children in our setting. Active case finding in young children detects uncomplicated 
primary complex TB with a small proportion of uncontained parenchymal disease. Growth 
failure is the clinical hallmark of uncontained pulmonary TB in young children in this setting. 
Although the overall proportions were low, hospital admissions and deaths due to TB are 
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The re-emergence of tuberculosis (TB) as a significant cause of morbidity and mortality, 
particularly in developing countries, has increased efforts to develop and test new and more 
efficacious vaccines against the disease. The existing vaccine against TB, the Bacille 
Calmette-Guérin (BCG) vaccine, which was first introduced about 90 years ago, confers 
protection against severe forms of TB in young children 
1-3
. However protection against 
pulmonary TB the commonest form of the disease is variable and largely poor, hence the 
large burden of TB even where BCG vaccination coverage is high 
4-8
. An example is South 
Africa, which has BCG vaccine coverage rates of up to 98%, and yet is one of the 22 high TB 
burden countries
4, 5
. In 2000 the case rate among children less than 15 years old was 237/100 
000 children and 502/100 000 population 
6
. In the Western Cape Province, in 2007, the 
incidence of childhood TB was estimated at 620/100 000/year 
9
. In 2005, the cumulative 
incidence of notified TB in children below the age of five years in three sub-districts in the 
Cape Winelands district where most of the studies described in this thesis were conducted 
was 2.4% (95%CI 2.2–2.6) 
10
. Furthermore, the BCG vaccine does not confer life-long 




Infants and young children are a special target group for new vaccines against TB, because 
they have a greater risk of developing TB disease and progressing to severe morbidity 
14, 15
, 
and because it would be cost-effective and logistically easier to integrate new vaccines into 
existing childhood immunization programmes. However, the assessment of the efficacy of 
new TB vaccines in children is significantly hampered by the absence of a biological 
correlate of protective immunity against TB 
16
, which means that the current end-point for TB 
vaccine trials is pulmonary TB disease. Howbeit, the detection of pulmonary TB in young 
children is challenging because the symptoms and signs are non-specific and overlap with 
those of other childhood illnesses. Bacteriological confirmation of the disease, the diagnostic 
gold standard, is limited by the paucibacillary nature of the disease in young children even in 
the advent of new diagnostic modalities 
17-20
. Furthermore, modern TB vaccine clinical trials 
are being conducted in an era where isoniazid preventive therapy (IPT) is recommended for 
children (and adults) with known exposure M.tb after exclusion of TB disease 
21
. IPT impacts 
on the natural progression of TB and its manifestation 
14
 making a definitive diagnosis more 






















to isoniazid a key compound in the treatment of TB 
27
. However in children the risk of drug 
resistance from IPT is unlikely because microbial load is generally low since disease is 




The conduct of TB vaccine trials, specifically phase II and phase III trials in young children 
therefore, requires robust, efficient and accurate case-finding and case-detection 
methodologies to ensure that vaccine safety and efficacy are determined accurately. 
Weaknesses in case detection and case ascertainment introduce the risk of misclassification 
bias which can dilute or obscure the true efficacy of the vaccine being tested.  
 
This PhD thesis explores methodologies for active TB case-finding, and TB case detection to 
inform the selection of case-finding strategies for clinical trials of TB vaccines conducted in 
young children, in high TB burden settings, in the 21st century. 
 
We calculated age-specific TB incidence in children less than 5 years of age in a high TB 
burden setting and investigated the effect of the categorization of TB case definitions on the 
measurement of the incidence of TB in these children. This work showed the highest 
incidence of TB to be in children aged one and two years old, with high rates maintained 
beyond the age of 24 months. This suggests that clinical trials of new TB vaccines given at 
birth could increase case accrual by extending follow-up and TB case-finding for at least 
three years. However most studies have limited participant follow-up until the age of two 
years because the risk of developing TB disease in children is greatest in those below two 
years of age 
14
, and because of resource constraints.  
 
We also investigated the impact of two active-case finding (ACF) strategies for TB on case 
yield and disease phenotype in children between birth and two years of age. Studies in adults 
have shown that ACF detects more cases and that they are less symptomatic than those 
detected passively 
30-36
. However, few studies on ACF have been conducted in children, and 
no studies had yet compared different active case-finding strategies in young children
 36-38
. It 
has therefore been unclear which case-finding strategies should be adopted in infant TB 
vaccine trials. We compared regular home visits for symptom screening for TB combined 
with medical record review (Group 1), with medical record review and a single screening 
visit at the end of the follow-up period (Group 2). Our hypotheses were that TB cases 

















visit at two years of age, resulting in a similar TB case yield in the two groups, and that the 
TB cases would differ in clinical, radiological and bacteriological features, due to an early, 
less severe disease phenotype detected by the more intensive strategy (Group 1). 
 
This study showed that regular home visits combined with record surveillance detected 
significantly more TB cases at a younger age than record surveillance alone with a single 
study end visit. However there was no significant difference in TB symptoms, signs, 
radiological and bacteriological profiles of TB cases in the two groups, and in both groups 
bacteriologically confirmed cases were few. We concluded that more intensive screening for 
TB, incorporating symptom based screening will maximise case detection in TB vaccine 
trials conducted in young children in similar settings. However, since bacteriologically 
confirmed cases were few, diagnostic algorithms based on symptoms, signs and other 
investigations should be highly specific to minimise misclassification bias which can dilute or 
obscure true vaccine efficacy.  
 
We also compared the utility of an interferon gamma release assay with the tuberculin skin 
test (TST) for detecting M.tb infection in children less than 3 years old who were suspected 
of having TB disease. These children were tested using the QuantiFERON-Gold-in-tube 
(QFT) assay and the TST in addition to other standard investigations for TB disease. We 
found excellent concordance between TST and QFT in this population. Both tests had much 
lower sensitivity than has been reported in older age groups 
39-41
. This finding suggests that 
the TST remains a useful test for detecting M.tb infection in populations and settings similar 
to ours. 
 
Given the likelihood of the adoption of ACF strategies in infant TB vaccine trials, the low 
likelihood of bacteriological confirmation of M.tb among TB suspects, and the role of chest 
radiography in the diagnosis of TB in children 
42
, we analysed the radiographic features of 
children with suspected TB who were identified through ACF. This analysis showed that 
ACF in young children in a high TB burden setting mainly detects isolated hilar 
lymphadenopathy, compatible with uncomplicated primary complex TB, rather than 
progressive pulmonary disease or severe TB as commonly reported in these settings 
37-43
. 
Growth failure was associated with lymphadenopathy and consolidation occurring in 
combination, suggesting that growth failure is a useful sentinel sign for detecting TB in ACF 

















radiologic abnormalities, highlighting the diagnostic difficulties associated with diagnosing 
TB in young children in infant TB vaccine trials. 
 
Modern TB vaccine field trials are being conducted in developing countries where the burden 
of childhood morbidity and mortality is high. Therefore we analysed the main causes of 
hospital admissions and mortality at a vaccine trial site in a rural setting with aim of detecting 
TB morbidity and mortality occurring among trial participants. We found a wide spectrum of 
morbidity and mortality that was however dominated by respiratory tract infections (RTIs). 
This suggests that without improved diagnostics for TB, it may be difficult to determine the 
true proportion of undiagnosed TB as it has been shown that pulmonary TB may be 





The findings of this thesis provide significant contributions to the subject of TB case-finding 
in TB vaccine field trials and other TB preventive studies conducted in infants and young 
children in high TB burden settings. Our findings show that; 
 
i) TB incidence in children is high throughout the first five years of life: - therefore clinical 
trials of new TB vaccines given at birth could increase case accrual by extending participant 
follow-up and TB case-finding for at least the first three years of life. 
ii) Intensive active case-finding strategies will maximise TB case detection in infant TB 
vaccine trials.  
iii) The TST remains a useful adjunct test for the detection of M.tb infection among young 
children with TB disease in high TB burden settings where the incidence of HIV is low. 
iv) Active TB case-finding in a high TB burden setting largely detects a mild chest 
radiographic TB phenotype, rather than the classical phenotype of severe disease commonly 
reported in high TB burden countries. This mild radiographic disease phenotype may reflect 
radiological changes associated only with M.tb, and not TB disease. Growth failure, rather 
than persistent cough, appears to be the clinical hallmark of uncontained pulmonary TB in 
young children. Therefore infant TB vaccine trials adopting active case-finding should 
prioritize growth failure as a sentinel clinical feature for early detection of childhood TB in 
high TB burden settings. 
v) The spectrum of morbidity and mortality among study participants at a TB vaccine trial 

















overall proportions were low, hospital admissions and deaths due to TB were significant 
contributors to serious adverse events in these trials. Despite extensive follow-up and data 
collection the ability to detect TB among trial participants who are hospitalised and those 
who may die is limited by the unavailability of better performing diagnostic tools for 
childhood TB. 
 
The studies reported in this thesis were conducted before molecular TB diagnostics were 
available, hence we cannot comment on their performance in infant TB vaccine trial settings. 
However paediatric studies on the Xpert/RIF in hospital settings have shown greater 
sensitivity and specificity compared to specimen culture (using mycobacterial growth 
indicator and the Lowenstein-Jensen methods), suggesting that these would be valuable in 
infant TB vaccine trials 
19, 47, 48
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1. To conduct a review of active case-finding strategies for TB in adults and children. 
(Chapter 2) 
2. To compare TB case yield and disease profile among Bacille Calmette-Guérin (BCG) 
vaccinated children from birth until two years of age using two active case-finding 
strategies. (Chapter 3). 
3. To compare results from the tuberculin skin test (TST) and the QuantiFERON®-TB Gold 
In-Tube assay (QFT) in young children investigated for TB disease in a high TB burden 
and low HIV setting. (Chapter 4).  
4. To describe chest radiographic features in young children with suspected pulmonary TB, 
in active case-finding in a high TB burden setting, and to identify the key clinical features 
associated with these radiographic phenotypes. (Chapter 5). 
5. To determine the nature and rate of serious adverse events, defined as hospital admissions 




















Chapter 1: General introduction 
 
 
Tuberculosis transmission and risk of disease 
Tuberculosis (TB) is caused by the Mycobacterium tuberculosis (M.tb) bacillus and is 
transmitted via droplet infection from individuals with active disease. Healthy individuals 
who inhale the bacilli may successfully resist infection, or become latently infected (latent 
tuberculosis infection, (LTBI)), whereby the bacilli are inactivated and lie dormant, or 
develop active TB disease (primary TB). Latently infected individuals may develop active 
TB (secondary TB) at a later stage. It is estimated that approximately 30% of the world 
population is latently infected with M.tb 
1
 The life time risk (among HIV negative 
individuals) of developing TB following infection with M.tb is estimated to be 10% 
2-4
, with 




Young children have a high risk of developing active disease following infection with M.tb 
because children generally have ‘immature’ immune systems than compared to adults, and 
are therefore less able to mount adequate responses to resist infection and the development of 
disease 
6-8
. This risk is greatest among the youngest children, with those who are less than 1 
year old having up to 40% risk of developing primary TB disease following exposure to M.tb 
in the absence of any preventiv  measures 
9
. In addition young children are at greatest risk of 
developing the severe forms of the disease namely miliary tuberculosis and tuberculous 
meningitis. 
 
Population groups with compromised immune systems are also at high risk of developing TB. 
In individuals who are infected with the human immunodeficiency virus (HIV) the risk of 
developing TB is 20-37 times greater than in those who are uninfected, and TB is the leading 
cause of mortality among HIV infected individuals, including HIV infected children. Other 
conditions that weaken the immune system such as malnutrition, cancer, stress also increase 
the risk of developing TB. TB is also a disease associated with poverty. Poor social 
conditions such as overcrowding and poor ventilation that facilitate the transmission of M.tb, 



















Tuberculosis in children 
Although the majority of cases of TB occur in adults, the large burden of childhood TB 
disease has been increasingly recognised over the past two decades. While young children 
with TB typically do not transmit disease and hence do not contribute to maintaining the TB 
epidemic, TB is a significant cause of morbidity and mortality in children 
5, 10-13
. Of the 9 
million annual TB cases in the world, it is estimated that about 1 million of these cases occur 
in children less than 15 years old 
12
. In high burden countries childhood TB contributes up to 
20% or more of the TB case load 
12
. Since the youngest children are at the highest risk of 
developing disease, the disease is thus largely borne by those less than 5 years old in high 
burden countries
 9
. In Cape Town, Moyo et al, found the highest incidence of TB in children 




Figure1: TB incidence rate by age among children less than 5 years old in Cape 
Town (1999-2004) Age related tuberculosis incidence and severity in children under 5 years of age in Cape Town, 




The youngest children are also at greatest risk of developing the more severe forms of the 
disease: - miliary TB and tuberculous meningitis, which can cause long lasting sequelae if not 

















al,) 11% of all children with probable and definite TB had disseminated disease, the largest 




In endemic settings children also experience a wide spectrum of TB disease manifestations 
and complications related to pulmonary disease. These include pleural disease, pericarditis, 
tuberculomas, airway compression, and dissemination to other organs such as the bones and 
the joints 
9, 15
. Children also experience significant TB mortality 
10, 16
. An audit of deaths in 
children <13 years old found TB to be a leading cause of death among children in South 
African hospitals, with 7% of all audited deaths attributed to TB 
16
. An autopsy study in 
young children dying from respiratory tract infections in Zambia, found TB to be a major 




Cases of childhood TB are important because they reflect recent infection and thus active 
disease transmission in the community since disease in children manifests relatively shortly 
after infection, commonly within one year of primary infection. Therefore, the incidence of 
childhood TB is a marker of TB control. An analysis estimating TB incidence rates in 
children <15 years old globally, revealed very high rates in 2000, with rates in five African 
countries exceeding 100/100 000 
11
. Although these estimates may now be outdated they 
nonetheless reflect sub-optimal control of the TB epidemic with on-going transmission of 
disease in high TB burden countries. 
 
Children who are infected with M.tb are a reservoir for later disease, because latent bacteria 
can be reactivated resulting in secondary TB later on in life 
9
. This has significant impact on 
the long-term control of the TB epidemic in the absence of a vaccine that can prevent 





TB control  
The global strategy for TB control is the World Health Organisation’s (WHO) STOP TB 
strategy 
19
. The strategy has six main components which are: 
i) Pursuing high-quality Directly Observed Treatment Short course (DOTS) 

















ii) Addressing TB/HIV and multi-drug resistant (MDR)-TB and other special 
challenges; 
iii) Contributing to health systems strengthening;  
iv) Engaging all care providers;  
v) Empowering people with TB, and communities; 
vi) Enabling and promoting research. 
 
In many high prevalence countries TB control has predominantly focused on the provision of 
DOTS and therefore has been targeted at the detection and treatment of infectious cases, 
largely adults who are the main transmitters of disease. In children, control strategies include 
vaccination with the Bacille Calmette-Guérin (BCG) vaccine, in countries with a high 
prevalence of TB, and contact tracing and prescription of isoniazid preventive therapy (IPT) 
to children less than five years old who have had close contact with an adult TB case, where 
appropriate evaluation has excluded TB disease 
12, 20
. Until recently in many of these 
countries TB control in children has largely consisted of BCG vaccination only, with poor 
implementation of contact tracing and IPT provision 
21, 22
. IPT is now also recommended for 




While IPT has been shown to be effective in preventing TB disease following exposure to 
M.tb, there are risks of adverse effects associated with its use
24-28
. A major concern is the 
development hepatotoxicity 
26-28
. However children have demonstrated better tolerance for 
TB drugs than adults, hence adverse events in children have been rare 
22, 25
. Secondly, 
although wide spread use of IPT creates risk of development of M.tb strains that are resistant 
to isoniazid, where TB disease has been excluded prior to initiation of therapy this risk is 
minimal 
26
. In children the risk of drug resistance from IPT is particularly unlikely because 






The BCG vaccine 
The BCG vaccine is currently the only vaccine available for protection against TB. The 
WHO recommends administration of BCG at birth in countries with a high prevalence of TB. 



















, protection against pulmonary TB is highly variable 
29-32
. Early trials of BCG 
reported vaccine efficacy ranging from 80%, indicating substantial protection, to -56%, 
indicating detrimental vaccine effects 
32-35
. A meta-analysis of clinical trials of BCG showed 




Variability in the protective efficacy of BCG with the lowest protection observed in countries 
with the highest incidence of TB has been attributed to a number of factors. These include 
genetic and nutritional differences between populations, geographic latitude, climate, 
differences in the strains of the BCG preparation used in the manufacture of the vaccine, poor 
cold chain management, and differences in exposure to environmental mycobacteria
 36-38
. It 
has also been postulated that BCG efficacy is reduced when given in the early neonatal 
period when the immune system is immature. Kagina et al showed improved BCG efficacy 
when vaccination was delayed to 10 weeks of age 
39
. However early administration is 
preferred in high TB burden countries because children may not return for vaccination at a 
later date and because exposure to M.tb occurs from a very early age.  
 
The current prevailing hypotheses for BCG failure are based on exposure to environmental 
mycobacteria, where it is postulated i) that exposure to environmental mycobacteria prevents 
any additional protective effect from BCG vaccination (the masking hypothesis) or ii) that 
pre-existing immune responses to antigens common to mycobacteria (induced by 





Severe cellular immune deficiencies have been associated with systemic or disseminated 
BCG disease following vaccination with BCG 
40
. This risk has also been demonstrated in 
HIV positive children and has been associated with a high rate of all-cause mortality 
41, 42
. 
Therefore BCG vaccination is not recommended for HIV positive children. However, a 
systematic review by Azzopardi et al, found the studies on BCG dissemination in HIV 
infected children to be heterogeneous and showed that data on the risk of BCG vaccination in 
this population are limited 
43
. This suggests that further studies and data on this topic are 
required. 
 
The sub-optimal protective efficacy of BCG and the safety concerns in HIV infected children 

















and testing of more effective vaccines against TB. This forms part of wider efforts directed 
toward new and improved strategies for TB control and prevention, given the prevailing high 
disease burden, poor treatment outcomes, the emergence of drug resistant strains of M.tb, and 
the high risk of TB among HIV positive individuals. The new vaccines being developed to 
combat TB are targeted at different age groups including infants and young children. Infants 
and young children are a special target group for new TB vaccines because of their greater 
risk of developing TB disease and because it would be beneficial (cost-effective and 




TB case-finding for clinical trials of new TB vaccines in young children 
As with trials of other therapeutic interventions, TB vaccine trials in infants and young 
children require sound and robust methodologies for randomization, blinding, subject follow-
up, subject assessment, case detection and case ascertainment, and statistical analyses, to 
ensure accurate determination of vaccine safety and efficacy. In the context of conflicting 
results of early BCG vaccine trials, Clemens et al conducted a statistical and methodological 
appraisal of eight early community trials of the BCG vaccine 
32
. He reported that poor 
precision and methodological flaws in the conduct of these trials resulted in various biases 
(susceptibility bias, detection bias, diagnostic bias, and diagnostic interpretation bias) that 
contributed to the conflicting data reported 
32
. Bias in the detection of TB cases was cited as a 
major source of vulnerability 
32
. Therefore, methodologies for detecting cases are a critical 
component of TB vaccine trials, particularly those conducted in infants and young children. 
Figure 2 illustrates the relationships between trial subjects, TB suspects and TB cases in a 























The detection of TB cases rests on the identification and evaluation of children suspected of 
having disease from the pool of trial subjects. However the signs and symptoms of 
pulmonary TB (PTB) in young children are non-specific making it difficult to identify 
suspects; hence the movement of trial subjects into the TB suspect and the TB case groups is 
critical. Secondly, in the context of vaccine trials, highly specific definitions for both suspects 
and cases are important to minimize disease misclassification which may dilute vaccine 
efficacy measurements. The current diagnostic gold standard (with high specificity) for TB 
disease is positive mycobacterial culture. However positive culture results are achieved in 
only 5–25% of children investigated for suspected TB 
44-47
. Therefore diagnosis also has to 
rely on diagnostic algorithms incorporating symptoms, clinical signs, chest radiographic 
findings and other investigations such as the tuberculin skin test, or interferon gamma release 
assays. These algorithms however, have limitations and have been shown to perform 
differently in different settings
 48-51
. Given the high costs of conducting clinical trials
 52
, it is 
imperative that surveillance methodologies detect TB suspects efficiently maximizing the 
likelihood of disease confirmation, the current TB vaccine trial endpoint. 
 
Figure 3 shows the interplay between surveillance intensity, the TB case detection rate and 
TB disease severity. Intensive surveillance increases TB case detection. However, it detects 
mild cases, for which diagnosis and therefore bacteriological disease confirmation is most 




















accurate case definition impact on the measurement of vaccine efficacy
 53, 54
. It seems 
unlikely that the relationship between these factors is a simple linear one, because there are 
many factors that impact surveillance intensity, the TB case detection rate and TB disease 
severity individually and collectively
 55
. These include the recognition and reporting of 
symptoms by parents, the duration of illness before reporting to a healthcare facility, and the 
recognition of TB symptoms and diagnosis by healthcare workers. The critical point for 
optimal surveillance intensity, case detection rate and disease severity therefore lies 
somewhere along the curve that is displayed in Figure 3.  
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Background: The persistently high burden of tuberculosis (TB) has increased interest in 
active case-finding for tuberculosis as a component of TB control, since it has been shown to 
increase case detection.  
Objectives: To conduct a review of active case-finding strategies for TB in adults and 
children.  
Methodology: We conducted a review of active case-finding methods for TB. 
Results: Approaches to active case-finding for TB involve either direct contact with 
individuals for screening, or the provision of information about TB and encouragement of 
symptomatic individuals to present to healthcare centres for screening. Strategies include 
contact tracing, mass radiography, outpatient screening, enhanced case-finding, and 
intensified case-finding. The majority of studies and evaluations of the various active case-
finding strategies have been conducted in adults. Studies in children have focused on contact 
tracing, which has been shown to be effective in detecting disease and latent TB infection in 
child and adult contacts when appropriately implemented. 
Conclusion: Although active case-finding detects more cases than passive case finding, there 





















The World Health Organisation’s (WHO) STOP TB strategy for TB control includes the 
Directly Observed Treatment Short Course (DOTS) program, where cases of TB are detected 
passively (passive case-finding (PCF)), with emphasis on the treatment of infectious cases to 
reduce disease transmission
 1
. PCF is the detection of TB cases among symptomatic 
individuals who self-present to healthcare centres
 2, 3
. It is patient initiated and thereafter 
relies on the ability of the health system to identify TB among those seeking care. However 
in PCF, TB cases tend to be detected at a late stage. The delay in the detection and 
subsequent treatment of cases leads to prolonged on-going transmission of M.tb, which has a 




The delay in presentation and initiation of treatment of infectious cases, the high prevalence 
of TB, the increased risk of TB in HIV positive individuals, poor adherence to treatment 
among TB patients, and the emergence of drug resistant strains of M.tb, have increased 
interest and focus on active case finding (ACF) for TB as a means of improving TB control 
through early detection and treatment 
5, 6
. Early detection and treatment of cases interrupts 
disease transmission thereby decreasing the infectious pool of M.tb bacilli
 2, 3, 7, 8.
 
 
ACF relies on the initiative or special effort by the health system to identify and evaluate 
people who would otherwise not seek care on their own initiative. It is based on direct contact 
with individuals and evaluation for TB on-site or shortly thereafter
 2, 9. ACF has been shown 
to detect cases of TB earlier than occurs in PCF
2
. It is therefore beneficial in TB control 
efforts since the early detection and treatment of infectious cases can reduce the number of 
subsequent and secondary cases of TB
 2, 3, 9, 10
. In children the distinction between M.tb 
infection and active TB disease can be difficult because making a definitive diagnosis of 
disease is more challenging due non-specific symptoms and signs and the paucibacillary 




A review focusing on the strengths, limitations, and the history future and prospects of ACF 
has previously been published 
2
. Presently, further work is being undertaken to update this 


















The objective of this chapter is to summarize ACF strategies for TB that have been used in 
adults and children. 
Review of active case finding methods 
Contact tracing 
Contact tracing is the identification and evaluation for TB disease of individuals who have 
had close contact with a recently diagnosed infectious case of TB (mostly smear positive 
adults). Thereafter, appropriate treatment is given: - curative therapy for those with TB 
disease and preventive therapy for those with latent TB infection (LTBI). Contact tracing has 
been considered to be the first logical extension beyond PCF, since it relies on the diagnosis 




While close contacts 
have traditionally been individuals living in the same household as the index TB case, it has 
however been shown that the definition of close contacts should also include non-house hold 
members who have had any prolonged or regular contact with the TB case, especially in high 
TB prevalence areas
 14
. Secondly, recent data demonstrate a need to broaden the definition of 





While in the majority of cases an adult is the index TB case, searching for 
contacts where a child is the index has also been shown to be valuable in detecting previously 




In developed countries contact tracing is routinely conducted on all contacts regardless of 
age, and has contributed to the decline and the maintenance of the low TB burden in these 
countries
 18, 19
. In developing countries, until recently, contact tracing within national TB 
programmes has focused only on young children (less than 5 years old), because of the higher 
risk of developing TB disease following exposure to M.tb in this age group
 13
. These 
countries have generally had limited resources for wider contact tracing, and provision of IPT 
beyond this age group. However, even among young children contact tracing is often not 
undertaken in many high TB prevalence settings, because of limited capacity for chest 
radiography and tuberculin skin testing which have traditionally been used for TB screening. 
Secondly, most national TB programmes have prioritized the management of infectious cases
 
20, 21
 leading to the relative neglect of contact tracing. To increase contact tracing among 
children in resource limited settings symptom based screening of child contacts is now 



















Furthermore, in the context of the HIV epidemic and the benefits of IPT, current policies 
strongly advocate regular screening for TB among HIV positive individuals and their 





Mass radiography entails taking chest radiographs (generally miniature radiographs) in large 
population groups as a screening measure for TB. Before the advent of effective 
chemotherapy against TB, mass radiography was a fundamental component of TB control in 
developed countries 
2, 28-33
. Entire communities and cities were surveyed 
30, 32, 33
. In 
developing countries mass radiography was mainly conducted in India 
34, 35
. Mass 
radiography was successful in detecting previously unknown cases of TB and diagnosing 
them earlier than would have occurred otherwise. The strategy was supported by specialised 
TB case management through dedicated TB units, and was effective in decreasing TB in 
developed countries. However, this could not be achieved in developing countries because of 
limited resources and infrastructure to support mass radiography and the accompanying 
specialised TB management units that existed in the developed world 
36
. Thus, although 
population surveys using mass miniature radiography may detect up to 90% of prevalent 
cases of TB in participating populations, the resource and logistical arrangements make these 
surveys very costly, and cost-ineffective when compared to other active case finding 
approaches 
37
. Mass radiography was therefore officially discouraged by the WHO Expert 




Chest radiographs have however remained an integral part of diagnostic algorithms for TB, 
and mass radiography has continued to be used in targeted settings; - namely TB prevalence 
surveys, screening for TB in schools and occupational settings, and screening of high risk 
groups, such as immigrants from TB endemic countries entering low TB incidence countries, 
drug users, the homeless and prisoners 
39-41
. In South Africa, 12 and 6-monthly radiographic 
screening were investigated and compared as ACF strategies among gold miners, a high risk 
group for TB 
42
. Six monthly screening detected less extensive disease and showed tendency 
toward lower TB-specific mortality 
42
. A recent TB prevalence survey in Kenya found a 
higher sensitivity for chest radiography than for symptoms alone, with the highest sensitivity 
being that for combined chest radiography and symptom screening 
43
. In the United 
Kingdom, digital chest radiography had very high sensitivity, specificity, and positive 


















.These findings underscore the value of chest radiography in these targeted settings 
44
. 
There is however limited evidence of the value of mass radiography for tuberculosis in 
infants and young children. This could be because chest radiographic interpretation is 
difficult and has low inter and intra-observer agreement 
45, 46
, in this age group.  
 
Enhanced case-finding 
During the era of mass chest radiographic screening for TB, developing countries mainly 
those in Asia began to investigate other strategies for ACF since they could not meet the 
requirements for mass radiography as was it practiced in the developed countries 
2, 47
. The 
focus was on detecting and screening symptomatic individuals only, rather than screening 
entire communities, a strategy termed enhanced case-finding (ECF),
2, 48
. By increasing the 
awareness of the population for TB symptoms and encouraging self-presentation to 
healthcare centres, ECF, has lower costs than mass radiography since only symptomatic 
individuals are seen and tested for TB. Awareness campaigns and educational activities about 
TB and TB symptoms in ECF have been undertaken through radio, television, newspapers, 
leaflets, and dramatization
 3, 49
. In Zambia, TB awareness and educational activities targeting 





ECF requires an alert health system that can detect TB among people presenting to health 
facilities as result of awareness campaigns and educational activities. However, it has been 
shown that screening for TB is not always conducted in eligible individuals seeking care at 
healthcare centres 
2, 51
. The WHO therefore recommends the Practical Approach to Lung 
Health (PAL), a syndromic approach to the management of patients attending primary health 
care (PHC) services for respiratory symptoms, which has been shown to increase screening 
for TB in PHC settings 
52, 53
. The standardization of diagnosis and treatment of respiratory 
conditions, and coordination among health workers at different levels of the health system in 
this syndromic approach, improves the quality of diagnosis for TB through the appropriate 





This form of ACF involves screening for symptoms and signs of TB among people attending 
outpatient departments of healthcare centres. This differs from ECF in that it need not be 

















people attending hospital are willing to seek care, but may not recognize that their symptoms 
are indicative of TB, and that these cases may not be detected by healthcare workers unless 
they are adequately trained and are aware of TB
 55-59
.  In Kenya more than 80% of TB cases 
detected through a door-to-door survey or interview of local leaders reported that they had 
attended a health unit while symptomatic but had not been diagnosed 
59
. Outpatient screening 
has been used in various out-patient settings including primary health care centres, district 
hospitals and antenatal clinics, and has detected a high burden of TB that would have 





Intensified case-finding, is a form of ACF that is being widely practiced in the context of 
human immunodeficiency virus (HIV) infection 
6, 8, 10
. It is a major component of key 
interventions that are aimed at decreasing the impact of TB among people living with HIV as 
part of the 3 I’s (Intensified TB case finding, Isoniazid preventive therapy, Infection control) 
strategy for HIV/TB 
6, 8, 10
. It is defined as the “regular screening of all people with HIV 
infection, or at high risk for HIV infection, or in congregate settings (such as mines, prisons, 
military barracks) for symptoms and signs of TB followed promptly with diagnosis and 
treatment”
 6
. Among HIV infected individuals it is recommended that this screening be 
conducted at every contact with a healthcare worker. In addition all household contacts of 





Comparison of ACF strategies  
Studies that have evaluated the impact of ACF, for TB have largely been conducted in adults, 
because adults have been the focus of TB control programmes as they aimed to decrease 
transmission by identifying and treating infectious cases
 3, 49, 61-68
.These studies showed that 
ACF increases the yield of cases, and that cases are detected earlier. In Brazil, door-to-door 
ACF using symptom screening and sputum collection detected more prevalent TB cases 
(9.3/1000py) and resulted in more people presenting for care than ECF that delivered a 
televised pamphlet to households (6.04/1000 py), rate ratio 1.55; 95% CI (1.10-1.99)
 49
. The 
leaflet described TB symptoms, advertised free TB services, and encouraged those with 

















using a mobile van to publicise educational leaflets and TB screening services detected 
significantly more smear-positive TB than door-to-door visits (mean cumulative TB yield 
4.22/1000 and 2.46/1000 adults per cluster respectively; OR 1.48; 95% CI (1.11-1.96))
 69
. 
Among South African gold miners, 6 monthly radiological screening for TB detected less 
extensive disease and showed tendency toward lower TB-specific mortality than 12 monthly 
screening 
42
. A Cape Town study that linked ACF to a mobile HIV service found a high TB 
case yield and had high treatment success:-the smear-positive TB prevalence was 2% among 




ACF has generally been noted to be more costly than PCF since it requires more resources to 
detect cases outside the health system. A historical review of ACF strategies noted that most 
studies had not included an assessment of the cost-effectiveness of these strategies 
2
. Recent 
studies on ACF have investigated and compared the costs of various ACF models 
2, 66, 70, 71
. In 
the study that linked ACF to a mobile HIV service, although the overall treatment success 





Cambodia, ACF targeting contacts of smear positive cases was found to be cost-effective in 
detecting cases in poor vulnerable communities 
66
. Dodd et al demonstrated that periodic 
ACF could improve control and save medium-term health care costs in high TB and HIV 





Active case finding in children 
Apart from contact tracing, few studies have evaluated other forms of ACF in young children. 
In Malawi, Zachariah et al compared ACF and PCF, and the uptake of isoniazid preventive 
therapy (IPT) among household contacts in a study that included both adults and children 
21
. 
PCF was defined as the prevailing local standard of care in the Malawi TB programme at the 
time. Symptomatic individuals self-referred to healthcare centres, and index cases were 
informed that all household contacts should attend hospital for evaluation and appropriate 
management. In the ACF cohort, the evaluation of household contacts was actively facilitated 
through the collection of sputum specimens at home, and the provision of referral slips for 
chest radiography for child contacts. ACF detected significantly more cases than PCF (1.74% 

















underwent chest radiography, (17%) received IPT, and none were diagnosed with TB. In the 
ACF cohort, 43% of child contacts identified underwent chest radiography, 25% received IPT 
and 4% were diagnosed with active TB and received curative TB therapy. 
 
Ward et al, reviewed routine TB data in Canada and compared cases detected passively 
through self-presentation, with those identified through contact tracing and high risk 
population screening surveys 
64
. This included preschool and school screening in 
communities with a high incidence of TB. There was no difference in age among the cases 
detected actively or passively; median age three years and two years respectively, p=0.3. 
Among those less than 19 years old, the cases detected by PCF were significantly more likely 
to report symptoms (cough, fever, weight loss, haemoptysis) than those detected by ACF.  
 
In a study that included adults and children, in Peru, ACF was conducted through visits to the 
homes of TB index cases, in comparison to household contacts being identified and advised 
to report to the local health centre if they experienced cough for more than two weeks (PCF) 
72
. No TB was diagnosed in children less than 15 years old in both groups. This was 
attributed to the fact that children could not produce sputum specimens required for 





ACF has been shown to increase the detection of TB cases. Various strategies for ACF have 
been evaluated in adults. The strategies include door-to-door household visits, ECF, out-
patient screening, and mass radiographic screening. Periodic ACF could offer medium term 
healthcare cost savings in high TB and HIV prevalence settings. Besides contact tracing 
which has been shown to be effective in detecting TB in children when appropriately 
implemented, there has been limited investigation of other ACF strategies in this population. 
There is therefore limited evidence to guide the selection of ACF strategies suited for young 
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Chapter 3: Comparison of two active case finding methods in young 
children in a high TB incidence setting: Implications for case finding 




Setting: A tuberculosis (TB) vaccine trial site in a high TB burden rural area in South Africa. 
Objectives: To compare TB case yield and disease profile among Bacille Calmette-Guérin 
(BCG) vaccinated children from birth until two years of age using two active case-finding 
strategies. 
Methodology: BCG-vaccinated infants were enrolled within 2 weeks of birth and 
randomised to 3-monthly home visits for questionnaire-based TB screening plus record 
surveillance of TB registers, hospital admission and X-ray lists at health facilities, for TB 
suspects and cases, (Group 1), or record surveillance (as above) only, (Group 2). Both groups 
received a close-out visit after 2 years. Participants were evaluated for suspected TB disease 
using standardised investigations.  
Results: A total of 4786 infants were enrolled: 2392 were randomised to Group 1 and 2394 
to Group 2. The case-finding rate was significantly greater in Group 1(2.2/100 py) than in 
Group 2 (0.8/100 py), with a case finding rate ratio of 2.6 (95%CI 1.8–4.0, P < 0.001). 
Although the proportion of cases with bacteriological confirmation was lower in Group 1, 
this difference did not reach statistical significance. There was also no significant difference 
in the proportions with TB symptoms and signs. 
Conclusion: Home visits combined with record surveillance detected significantly more TB 
cases, at a younger age, than record surveillance alone with a single study end visit. There 
was no significant difference in the TB symptoms, signs, radiologic and bacteriologic profile 
of TB cases in the two groups. Regular screening for TB combined with record surveillance 





















It has been established that active case-finding (ACF) for tuberculosis (TB) increases case 
detection and detects cases that are less symptomatic than those detected passively
 1-4
. More 
recent studies have compared various ACF methods, and some have evaluated the costs of 
different ACF methods
 5-9
. The high case yield from ACF makes it likely to be the preferred 
case-finding strategy in clinical trials of new TB vaccines as well as in other TB preventive 
studies conducted in young children. The greater number of cases that would be detected in 
ACF increases study efficiency by reducing sample size requirements (in comparison to 




In young children, case finding studies have largely focused on the yield of contact tracing 
(which can be considered a form of ACF), in households of smear positive adults
 11-13
. Few 
studies have investigated or compared other forms of ACF with PCF in children
 3, 4
. In 
Malawi, ACF detected more cases in all ages (adults and children less than 6 years old), than 
PCF. More children in the ACF group were screened and prescribed preventive and curative 




Since there are limited data on ACF strategies in young children, it is not clear what ACF 
strategies should be adopted in TB vaccine trials conducted in young children. Differences in 
adult and childhood TB restrict the direct application of some of the ACF strategies that have 
been successful in adult studies. Firstly, TB symptoms in children are non-specific and 
overlap with those of other childhood conditions especially in the very young children, hence 
where symptom screening is adopted for ACF in children, this must be designed to have high 
specificity in comparison to that used in adults
 14-17
. Secondly while adults can fairly easily 
produce sputum samples for microbiological testing for M.tb, this is more difficult to achieve 
in children, hence household sputum sample collection is not feasible in this population. 
Furthermore, since TB in children is paucibacillary, gastric washing (GW) samples or sputum 
samples collected by the more effective induction of sputum (IS) techniques yield very few 
bacteriologically confirmed cases. It is also worth noting that sputum induction techniques 




The study described in this chapter aimed to compare the case yield of two active TB case-

















TB cases remaining undetected by the less intensive strategy would be found at a close-out 
visit at two years of age, resulting in similar TB case yields in the two groups, and that ii) the 
TB case profile would differ in clinical, radiological, and bacteriologic features, due to an 





The study was conducted between 2005 and 2008, in the Cape Winelands district (~100km 
from Cape Town) of South Africa. The population in the study area during 2007-2008 was 
estimated at 327,822 
21
. The annual birth cohort is estimated at 7000 births. The region is 
well serviced by clinics and hospitals including a regional specialist TB hospital. The overall 





Healthy infants vaccinated with Bacille Calmette-Guérin (BCG) vaccine (intradermal Danish 
strain 1331, Statens Serum Institut, Denmark), within 72 hours of birth, were enrolled within 
two weeks of birth. Enrolment took place at birthing units (clinics or hospitals) or at home. 
Infants were randomized in a 1:1 ratio to Group 1 or Group 2 case-finding (described below) 
using simple random allocation. After obtaining consent from a parent or legal guardian, field 
workers telephoned the study administrator for the infant’s randomization group and study 
number. These were assigned from a pre-generated randomization list. Follow-up was 
scheduled for at least two years. Recruitment took place between 2005 and 2006 and follow-
up was completed in 2008. 
 
Case finding strategies 
Group 1 - Home visits and record surveillance 
The ACF strategy in this group entailed 
i) home visits every three months for questionnaire based screening for TB symptoms and 
contacts. Participants were considered TB suspects if they reported close contact with an 
adult TB source case or at least one of the following symptoms for a period greater than 2 

















ii)  surveillance of TB registers in all clinics in the study area for adult TB cases in contact 
with study participants ( as shown by the same home address), and for participants 
diagnosed with TB, 
iii) surveillance of hospital admission name lists in all hospitals in the study area for study 
participants seen or admitted and diagnosed with TB or TB related conditions such as 
respiratory tract infections, 
iv) surveillance of clinic and hospital x-ray department name lists to identify participants 
who had undergone chest radiography (CXR) during health centre attendance.  
 
TB suspects and cases identified from the records described in ii-iv, above were visited at 
home (in addition to the regular three monthly visits) to verify these findings. All suspects 
and cases were referred to a study research ward for further evaluation and investigations for 
TB disease. Investigations were prioritized for those who had already been diagnosed with 
TB at local clinics or hospitals.  
 
Group 2 - Record surveillance 
ACF in this group involved all aspects of record surveillance as described for Group 1, but 
excluded the three monthly home visits. Suspects and cases were referred to the research 
ward for further evaluation and investigations for TB disease as for Group 1. 
 
Both groups 
In both groups, parents or guardians could contact the study team directly if they suspected 
their child had TB symptoms or a TB contact. Healthcare workers in the area could also refer 
participants (identifiable by study stickers attached to the Road-To-Health-Card at enrolment) 




Attempts were made to contact each participant to administer a TB symptom and contact 
screening questionnaire at a close-out visit scheduled at two years of age. Four attempts were 
made to contact each participant.  Admission into the research ward for investigations for TB 
disease was extended to the age of 26 months to allow sufficient time for all close-out visit 



















Evaluation and investigations for TB disease 
Participants with suspected TB disease during follow-up, or at the close-out visit, were 
admitted to a research ward for investigations over three days. A medical history and 
examination were performed by a clinician and the following investigations conducted: CXR 
(anterolateral and antero-posterior films), tuberculin skin test (TST) by the Mantoux method, 
Human Immunodeficiency Virus (HIV) testing (with parental/legal guardian consent), paired 
early morning GW and IS specimen collection on two consecutive days. Smear microscopy 
(auramine fluorescent microscopy) and culture for Mycobacterium tuberculosis (M.tb) 
(Mycobacterial Growth Indicator Tube (MGIT) 960) were performed on all GW and IS 
specimens. Cultures were incubated for at least 6 weeks. Positive cultures underwent 
speciation to exclude non-tuberculous mycobacteria (NTM). The TST was read 48-72 hours 
after administration.  
 
All children who were admitted into the research ward were managed using results available 
during admission and at the time of discharge, by the research ward clinician. The clinical 
management of these children was independent of the study processes. Those diagnosed with 
TB disease by the research ward clinician were started on curative TB therapy. Those 
diagnosed with latent tuberculosis infection (LTBI) were started on preventive TB therapy. 
Upon discharge, participants were referred to the regular healthcare system for further 
management. Sputum microscopy and culture results that arrived after discharge were 
forwarded to the appropriate public health clinics to inform continuing patient management. 
Study follow-up continued until the end of study (close-out visit) for all participants 
including those who had been had been evaluated for TB in the research ward. 
 
For the purposes of this study, TB diagnosis was classified into, “Definite TB”, “Probable, 
TB”, “Possible TB”, or “not TB”, using a diagnostic algorithm based on history, examination 
and the results of investigations conducted, as shown in Figure 1. For this classification, 
CXRs were reviewed independently by a panel of three paediatric radiologists who were 
blinded to the clinical information. Readings were based on and recorded on a predesigned 
CXR reading and recording form (Appendix 2). CXR findings were categorised as; “TB-
Present” (CXR findings consistent with TB); “TB-Not present” (no CXR findings consistent 
with TB, or findings for and against TB equivocal, or CXR not readable). Airway 

















cardiac regions, and miliary nodules were considered definitive evidence of TB. A final CXR 




The study was approved by the University Of Cape Town, Faculty of Health Sciences Human 
Research Ethics Committee (Cape Town, South Africa), and the Chesapeake Research 









































































DEFINITE TB POSSIBLE TB NOT TB 
1
Excludes scanty and 1+ smear positive,  
2
X-ray reading based on paediatric radiologist panel final chest x-ray finding, 
3
Additional features: Mantoux ≥10mm (5mm if HIV infected), Cough >2 weeks, Failure to thrive (defined as 
persistent inadequate weight gain or persistent weight loss determined by the research ward clinician on review of 
the Road to Health Card), TB contact 



















Statistical considerations and analysis 
Sample size 
We calculated that 2620 infants in each group would detect a 1% absolute difference in rates 
between the groups (Group 1 disease detection estimated at 2% and Group 2 at 1%), at 80% 
power and α = 0.05. The sample was reduced to 2400 in each group because of financial and 




Data were analysed using STATA version 10.0 (Stata Corp College Station, Texas, USA). 
Rate ratios were calculated for the primary analysis. Odds ratios were calculated to compare 
TB clinical features in suspects and cases between the groups; 95% confidence intervals and 
p values were calculated. The t-test was used to compare continuous variables, since the 
sample size was fairly large. The case finding rate was calculated as cases detected over 
person-years of follow-up. Person-years were calculated from date of birth until the date of 
TB diagnosis, death or the close-out visit, whichever was first. For participants lost to follow-
up (LTFU), person-years were calculated as midway between the last contact date and date of 
the next expected visit (3 monthly or close-out), and for those who withdrew, from the date of 
birth to date of withdrawal. Sensitivity analyses under various assumptions about length of 
follow-up and the TB status of participants LTFU were also performed. 
 
For those participants with multiple admissions to the research ward, the admission with the 
more severe TB classification was analysed; otherwise, the first admission was used. Only 
definite and probable (DP) cases of TB were included in this analysis as they were considered 
as the most robust case definitions. Study participants who were diagnosed with TB outside 
the research ward were not included in the primary analysis, since the diagnostic methods 
differed from those in the health system. Sputum induction was not conducted, GW was not 





















A total of 4786 infants were enrolled: 2392 were randomized to Group 1 and 2394 to Group 
2. Table 1 summarizes the baseline characteristics of participants in the two groups.  
 
Table 1: Baseline characteristics of all participants enrolled (N=4786) 







Males 1205 (50.4) 1199 (50.1) 
Low birth weight (<2.5kg) 437 (18.3) 430 (18.0) 
Mean maternal age at infant’s birth (years) 
 
26.5 (SD= 6.7) 26.3 (SD= 6.7) 
Mother level of education (Primary level and 
lower) 
 
631 ( 26.4) 610 (25.5) 
Peri urban residential area§  399(16.7) 384(16.0) 
Informal housing  306 (12.8) 288 (12.0) 
‡
Home visits and record review, 
‽
Record review only, 
§
Informal settlements situated at periphery of formal 
urban housing, SD-standard deviation 
 
 
The proportion of deaths, withdrawals, and LTFU were similar in the two groups, as shown 

























Case finding rates 
Twenty-three participants (11 Group 1; 12 Group 2) were diagnosed with TB outside the 
research ward and were excluded from the primary analysis because of insufficient 
information to apply the study diagnostic algorithm. Mean follow-up time was 20.7 months 
in Group 1 (standard deviation (SD) 8.2) and 22.0 months in Group 2 (SD 6.8). Eighteen 
percent of participants (527 Group 1; 353 Group 2) were admitted to the research ward. 
Among these 880 children admitted to the research ward, eight (0.9%) children (5 Group 1; 3 
Group 2) were HIV positive.  
 
The overall case finding rate was significantly higher in Group 1, (case finding rate ratio 2.6 
(95% CI 1.8-4.0), p< 0.001) as shown in Table 2A. There was no significant difference in the 
case finding rate in the youngest (0-6 months) and the oldest age categories (18-26 months). 
Participants enrolled 
N=4786 
Group 1(Home visits and record review)  
n = 2392  
 
Died = 57 (2.4%) 
Loss to follow up = 352 (14.7%) 
Withdrew = 6 (0.3%) 





Group 2 (Record review only) 
n = 2394 
Died = 62 (2.6%) 
Loss to follow up = 367 (15.3%) 
Withdrew = 13 (0.5%) 


















Table 2A: Case finding rates by randomisation group (N=4763)# 
 ‡Group 1  
n=2381 
‽Group 2  
n=2382 
Case finding 





No. of TB cases 
Total (definite; 
probable) 
Pys  Case finding 
rate/100pys 
(95% CI) 
No. of TB cases 
Total (definite, 
probable) 




         
0-6 11 (2; 9) 
 
1133 1.0 (0.5-1.7) 5 (2;3) 1168 0.4 (0.1-1.0) 2.3 (0.7-8.3) 0.06 
6-12 28 (5 ;23) 
 
1008 2.8 (1.9-4.0) 7 (4;3) 1120 0.6 (0.3-1.3) *4.4 (1.9-12.1) *<0.001 
12-18 24 (1;23) 
 
905 2.7 (1.7-3.9) 4 (0;4) 935 0.4 (0.1-1.1) *6.2 ( 2.1-
24.6) 
*<0.001 
18-26 26 (2;24) 
 
1063 2.4 (1.6-3.6) 20 (2;18) 1149 1.7 (1.1-2.7) 1.4 (0.8-2.7) 0.13 
         
0-26 89 (10;79) 
 
4109 2.2 (1.7-2.7) 36 (8;28) 4372 0.8 (0.6-1.1) *2.6 (1.8-4.0) *<0.001 
         
#
23 children diagnosed with TB outside the study research ward were excluded due to insufficient clinical 
details, 
‡
Home visits and record review, 
‽
Record review only, *statistically significant, pys- personyears, CI- 




Sensitivity analyses taking into account different scenarios regarding loss to follow-up and 
disease status were also conducted. This analysis covered the entire study period 0-26 
months. The results were similar to those found in the primary analyses (above) and are 
shown in Table 2B; where the more intensive strategy (Group 1) detected significantly more 





















Table 2B: Sensitivity analyses: Case finding rates by randomisation group (0-26 
months) 
 ‡Group 1  
 






















TB cases diagnosed outside 
the research ward excluded 
 
n=2381 n=2382   
Participants lost to follow up 
do not have TB disease, and 
are censored at the date of 
last contact 
 
89 4072 2.2 (1.8-2.7) 36  4120 0.9 (0.6-1.2) *2.5 (1.7-
3.8) 
*<0.001 
Participants lost to follow up 
do not have TB disease, and 
have completed the study 
 
89 4445 2.0 (1.6-2.5) 36 4621 0.8 (0.5-1.1) *2.6 (1.7-
3.9) 
*<0.001 
Participants lost to follow up 
have TB disease, and length 
of follow-up as in the primary 
analysis 
 
441 4109 10.7(9.8-11.7) 403 4372 9.2 (8.4-10.1) 1.2 (1.0-
1.3) 
*0.01 
Participants lost to follow up 
have  TB disease, and are 
censored at the date of last 
contact 
 
441 4072 10.8 (9.9-
11.8) 
403 4120 9.8 (8.9-10.7) 1.1 (1.0-
1.3) 
0.07 
Participants lost to follow up 
have TB disease, and have 
completed the study 
 
441 4445 9.9 (9.1-10.8) 403 4621 8.7 (7.9-9.6) 1.1 (1.0-
1.3) 
* 0.03 
TB cases diagnosed outside 
the research ward included 
 
n=2392 n=2394   
Cases diagnosed outside the 
research ward included, 
participants lost to follow up 
do not have TB disease and 
length of follow-up as in the 
primary analysis 
 
100 4123 2.4 (2.0-2.9) 48 4383 1.1 (0.8-1.4) *2.2 (1.6-
3.2) 
* <0.001 
Cases diagnosed outside the 
research ward included, 
participants lost to follow up 
have TB disease and length of 
follow-up as in the primary 
analysis 
452 4123 11.0 (10.0-
12.0) 
415 4383 9.5 (8.6-10.4) 1.2 (1.0-
1.3) 
*0.02 
Home visits and record review, 
‽




Comparison of clinical features 
We compared clinical features between TB suspects and cases in the two groups. The results 
are shown in Table 3. Significantly more TB suspects in Group 1 had CXR abnormalities 

















proportion of bacteriologically positive cases was lower in Group I, there was no significant 
difference in the proportions with TB symptoms, clinical and radiological signs, and positive 
bacteriology between the groups. Age at TB diagnosis was 13.2 months (SD 6.3) in Group 1, 




Table 3: Clinical profile of suspects and cases 
 TB suspects TB cases 
 
Variable ‡Group 1 
n= 527 (%) 
 
‽Group 2 
n= 353 (%) 
OR 
(95% CI) 
p value ‡Group 1 
n= 89 (%) 
‽Group 2 











































































































































Home visits and record review, 
‽
Record review only,*statistically significant, OR- odds ratio, +ve- positive, CI- 
confidence interval, CXR- chest x-ray, Y- yes, N- no, UNK- unknown/missing, Failure to thrive was defined as 
persistent inadequate weight gain or persistent weight loss determined by the research ward clinician on 
review of the Road to Health Card, 
π
Mycobacterium tuberculosis culture or smear positive, excluding scanty 
and 1+ smear positive, ΔPercentages do not add up to 100% because of rounding off errors. The N (no) 
category is the reference group for each odds ratio. 
 
 
Preventive TB therapy 
Six percent and 9% of suspects in Group 1 and 2, respectively, were on preventive or curative 
TB therapy at the time of evaluation in the research ward (p=0.06). A significantly greater 
proportion of participants in Group 1 were prescribed curative TB therapy (11% Group 1 vs 
7% Group 2, (p< 0.001)) on discharge from the ward.  
 

















Table 4 shows the number and percentage of suspects and cases by method of detection 
within the two strategies. Three monthly home visits detected most of the cases (56%) in 
Group 1, while in Group 2, the close –out visit detected just over a third of the cases. The 
various forms of record surveillance combined (TB register review, hospitalisation record 
review, X-ray list review) detected 53% of cases in Group 2.  
 
 
























Home visit  303 (58) 50 (56) N/A N/A 
Close out visit 33 (6) 4 (4) 98 (28) 13 ( 36) 
TB register review 56 (11) 12 (13) 95 (27) 10 (28) 
Hospitalisation record review 56 (11) 7 (8) 63(18) 5 (14) 
X-ray list review 24 (5) 6 (7) 43 (12) 4 (11) 
Clinic referral 23 (4) 3 (3) 30 (9) 4 (11) 
^Self-reporting 18 (3) 4 (4) 13 (4) 0 (0) 
Combination of methods 12(2) 3 (3) 3 (0.9) 0 (0) 
Other/Method not  recorded 2 (0.4) 0 (0) 8 (2) 0 (0) 
#
23 children diagnosed with TB outside the study research ward were excluded due to insufficient clinical 
details, 
‡
Home visits and record review, 
‽
Record review only, 
^




NTM were detected in 6% (32/527) children who were investigated for tuberculosis. None of 
these children had M.tb. Eight strains of NTM were detected. These are shown in Table 5 
below. In 18 children, the NTM could not be identified. However BCG disease was excluded 




















Table 5: Non-tuberculous mycobacteria isolates obtained from gastric lave or induced 
sputum specimens in children investigated for tuberculosis (n=527)  
Non-Tuberculous mycobacteria species n (%) 
M intracellulare 6(1.1) 
M gordonae 3 ( 0.6) 
M peregrinum 3 (0.6) 
M asiaticum 1 (0.2) 
M chelonae 1(0.2) 
M kansasii 1(0.2) 
M scofulaceum 1(0.2) 




Both groups reported a similar proportion of deaths (2.4% in Group 1 and 2.6% in Group 2). 
Pneumonia, gastroenteritis and septicaemia were the leading causes of mortality in both 
groups also reported in similar proportions in the two groups. For the purposes of this study 
causes of deaths were assigned based on clinical records, a verbal autopsy interview and a 
complete (unabridged) death certificate, where these were available. Accurate cause of death 
information based on the documents mentioned above was not available in 26% of deaths in 




Home visits combined with record surveillance detected significantly more TB cases and at a 
younger age than record surveillance alone, even when a close-out visit allowed detection of 
cases that were potentially missed during the period of follow-up. Sensitivity analyses also 
found a significantly higher case yield from home visits combined with record surveillance.  
The case finding rate in the 18–26 month age category, which included TB cases found at the 
close-out visit, was similar between the two groups. Although the proportion of cases with 
bacteriologic confirmation was lower in Group 1, the difference did not reach statistical 
significance. There was also no significant difference in the proportion of participants with 
TB symptoms and signs in both case finding strategies.  
 
Our study shows the value of regular screening for TB through home visits in detecting TB 

















a large number of cases in Group 2, the overall case finding rate in Group 2 was significantly 
surpassed by that in Group 1. A Phase IV infant trial conducted in the same community and 
used record surveillance similar to that for Group 2, reported a cumulative DP TB incidence 
rate of 3% over two years
 22
. This rate is lower than that in Group 1 (4% over 26 months), and 
higher than in Group 2 (2% over 26 months). Together with our finding that 36% of cases in 
Group 2 were detected at the close-out visit, this demonstrates the value of home visits in 
detecting additional cases of TB, which is important in trials of TB vaccines.  
 
Although home visits detected most cases, our findings show that to maximise case detection, 
an important requirement in TB vaccine trials 
23-25
, record surveillance is also required. 
Eighteen percent of cases in Group 1 self-referred to a healthcare centre (clinic referral, 
hospitalisation, and x-ray list review), (Table 4), despite regular contact with study staff, 
demonstrating the usefulness of record surveillance. These cases may have been undetected 
in the absence of record surveillance. 
 
We had hypothesized that cases detected at an earlier age, by the more intensive case finding 
strategy, would present with milder clinical and radiological disease. Instead, we found 
significantly more suspects with radiologic abnormalities consistent with TB in Group 1, 
although this difference was not statistically significant among cases. This difference between 
suspects in the two groups might be due to transient radiological evidence of the primary TB 
complex that self-cures without intervention. This is consistent with the natural history of TB 
infection and disease in young children, wherein children recently exposed to M.tb may 
develop transient radiological changes 
26-30
. Nonetheless, these data show that a case finding 
strategy that includes regular home visits identifies children who are exposed to M.tb much 
earlier than would occur otherwise. This is important because children less than 2 years old 
are at greatest risk of progressing to severe or disseminated TB disease following exposure to 
M.tb 
26
. No cases of severe or disseminated TB were detected in both groups, indicating that 




Despite using IS in addition to GWs to collect specimens for microscopy and culture for 
M.tb, we only had a few bacteriologically confirmed cases 
18
. Although this could be partly 
because some participants had started TB therapy at the time of evaluation, these were few 
(7%) and evaluations were conducted within a few days of initiation of treatment. This 

















history, clinical and radiologic features, as bacteriologically confirmed cases are likely to be 
few 
22
. However, there are challenges and limitations in using clinically based definitions in 
research settings, and these have been well described in the literature 
27, 31-35
. These include 
poor specificity and varying performance of the algorithms in different settings 
31, 32
. While 
these diagnostic algorithms may be appropriate in clinical settings within specific 
environments, in TB vaccine trials they introduce the risk of disease misclassification which 
could have significant bearing on the measures of efficacy that are calculated. Differential 
misclassification can either under or over-estimate efficacy (depending on its direction) while 
non-differential misclassification can mask a moderate effect 
10, 23, 36
. Recent publications 
from expert groups have attempted to build consensus and standardize TB case definitions in 
research settings to increase specificity and reduce the risk of disease misclassification in TB 




The mortality profile in this study reflects that found in the same community in a previous 
study 
37
. Mortality was dominated by pneumonia and diarrhoeal disease. It is notable that in 
the less intensive strategy, there were more cases without accurate cause of death 
information, despite the extensive follow-up methods used in the study. It is possible that 
some of these deaths could have been due to TB or could have happened in children with TB, 
and this could therefore represent undetected cases. While both groups were cases affected, it 
is likely that proportionally more of these cases would have been in the less intensive case-
finding group where contact with participants was minimal. 
 
The 6% crude NTM yield is similar to what was found in previous study in the same 
community 
38
. However there was slight difference in the species detected.  
 
This study had some limitations. Not all children were seen at the end of study; therefore, 
some TB cases or deaths may have been missed. However, since the overall findings 
remained unchanged in sensitivity analyses and the proportion of deaths did not differ 
between groups, the impact was probably the same and minor for both groups. The 23 
children missed by our case-finding strategies and were diagnosed with TB outside the 
research ward may have had more severe disease. These participants self-reported to 
healthcare centres and were diagnosed with TB. However review of their clinical records 
revealed insufficient information to apply the study diagnostic algorithm. Seven percent of 

















five percent of participants evaluated in the research ward were prescribed preventive therapy 
on discharge. Both factors could have reduced the number of cases in both groups. This study 
was limited to two years of follow-up, while we have previously shown that TB incidence is 
still high in the third year of life 
25
. Additional follow-up might have provided additional 
cases and additional data on the profile of cases and disease severity. There was a small 
number of TB cases (89 cases in Group 1 and 36 cases in Group 2) detected and this may 
have been inadequate to detect differences in the profile of cases in the two groups. Extended 
follow-up or a larger sample size would be required to investigate this further. A larger 




Home visits combined with record surveillance detected significantly more TB cases, at a 
younger age, than record surveillance alone with a single study end visit. There was no 
significant difference in the TB symptoms, signs, radiologic and bacteriologic profile of TB 
cases in the two groups. Regular screening for TB combined with record surveillance will 
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Chapter 4: Tuberculin skin test and QuantiFERON assay in young 




Setting: A tuberculosis (TB) vaccine trial site in high TB burden rural area in South Africa. 
Objectives: To compare results from the tuberculin skin test (TST) and the QuantiFERON-
TB Gold In-Tube assay (QFT) in young children investigated for TB disease in a high TB 
burden setting. 
Methodology: TB suspects were evaluated by medical history and examination, TST, QFT, 
chest radiography, induced sputum and gastric washings for smear and culture for 
Mycobacterium tuberculosis (M.tb).  
Results: Four hundred children were enrolled. Among 397 children with both test results, 68 
(17%) were QFT result positive and 72 (18%) were TST result positive (≥10 mm). 
Agreement between the tests was excellent (94%; κ = 0.79 (95% CI 0.69-0.89)). TB disease 
was diagnosed in 52/397 (13%) participants: 3 definite, 35 probable, and 14 possible TB. 
QFT sensitivity and specificity for M.tb infection in children diagnosed with TB disease were 
38% and 81% respectively. TST sensitivity and specificity were 35% and 84% respectively.  
Conclusion: While TST and QFT had excellent concordance in this population, both tests 
had much lower sensitivity than has been reported for other age groups. Our results suggested 
equivalent performance of the QFT and the TST in detecting M.tb infection in children with 





















Establishing a definitive diagnosis of pulmonary TB in young children is challenging because 
disease is pauci-bacillary and specimen collection more difficult compared to adults 
1, 2
. 
Although there have been advances in techniques (such as sputum induction) to collect 
sputum specimens, and in techniques to detect Mycobacterium tuberculosis (M.tb) in these 
specimens, disease confirmation by positive M.tb culture remains a challenge where TB 
suspects are not severely ill such as in research settings undertaking active case-finding for 
TB 
3, 4
. In the absence of M.tb culture confirmation, the diagnosis of pulmonary TB in 
children continues to rely on diagnostic algorithms that include history of exposure to M.tb, 
the tuberculin skin test (TST), or interferon gamma release assays (IGRAs), clinical, and 
radiological features
 1, 2, 5, 6
. However clinical features for the diagnosis of TB in children are 
unreliable 




Although a positive TST result is only indicative of infection with M.tb, and therefore 
indicates latent TB infection (LTBI), it is a useful adjunct test for TB disease since a positive 
result indicates recent infection which in young children is strongly associated with a high 
risk of progression to TB disease 
7
. The interpretation of the TST result is however 
confounded by infection with environmental mycobacteria, Bacille Calmette-Guérin (BCG) 
vaccination, the immune status, and by the techniques used to administer the test and to read 
results. IGRAs which are largely unaffected by previous exposure to environmental 
mycobacteria and BCG have now been developed for the diagnosis of LTBI. These assays 
have increased specificity for detecting infection with M.tb. This is important in TB vaccine 
trials as it has potential to minimise disease misclassification (false positivity), that could 
result from the use of TST results in clinically based TB suspect and case definitions.  
 
Initial testing of IGRAs was largely been conducted in adults 
8-27
, with relatively limited 




The main objectives of the study described in this chapter were to compare the sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) of the TST 
and the QuantiFERON-TB Gold In-Tube assay (QFT) in children less than 3 years old, in a 

















compare the absolute interferon gamma (IFN-γ) levels in children with various risk factors 





Children included in this study had been enrolled in a study that compared two active case-
finding (ACF) strategies on the incidence of TB in children aged 0-2 years old. (This study is 
described in Chapter 3). The study was conducted between 2005 and 2008, in a rural district 
of the Western Cape Province, about 100 km from Cape Town, South Africa. The population 
in the study area during 2007-2008 was estimated at 327,822 
29
. The overall TB incidence 
was 1442/100000 and antenatal HIV prevalence 12.8% in 2007 
29
. South Africa has a policy 






Convenience systematic sampling was used select the study participants, because funding 
was limited. Among the 4786 children enrolled in the ACF study, 400 children sequentially 
investigated for TB disease in the study research ward between July 2007 and September 
2008, were included in the study. The participants had been identified for TB investigation by 
either of the case detection strategies described in Chapter 3. 
 
Investigations 
Investigations for TB were undertaken in a dedicated research ward as described in Chapter 
3. However for this study in addition to all other investigations, a blood sample was also 
drawn for the QFT assay. Chest radiographs (CXRs) were reviewed independently by three 




The qualitative QFT was performed in accordance with manufacturer’s instructions – this 

















response of ≥0.35 IU/mL for TB antigens, after subtracting values for the negative control. 
While the assay read-out provides absolute levels of IFN-γ, high values above 4IU/mL, the 
highest standard provided cannot be precisely measured 
31
. Therefore, we stored QFT 
supernatants at -20°C, and later determined the quantitative IFN-γ levels in all participants 
again, using serial plasma dilutions. The optimal dilution determined in preliminary 
experiments was 1:25. Samples with indeterminate results were not repeated because a 
limited number of kits were available. 
 
Definitions 
Children were categorized as having “TB disease” or “No TB” based on an algorithm that 
included history of close household contact with a TB source case (household TB contact), 
clinical features suggestive of TB on medical examination, and CXR findings consistent with 
TB. The clinical features suggestive of TB were defined as cough for a period greater than 2 
weeks or failure to thrive. Failure to thrive was defined as persistent inadequate weight gain 
or persistent weight loss determined by the research ward clinician on review of the Road to 
Health Card. TB disease included cases classified as having “Definite TB”, “Probable TB”, 
and ”Possible TB” which were defined as follows; 
- definite TB:- bacteriologically confirmed cases (culture or smear positive); 
- probable TB:- CXR findings consistent with TB and ≥1 clinical features suggestive of 
TB, or a household TB contact ; 
- possible TB: - CXR findings consistent with TB only, or ≥2 clinical features 
suggestive of TB only or 1 clinical feature suggestive of TB and a household TB 
contact in children prescribed standard TB therapy by the treating clinician. 
 
(CXR findings are described in detail in Chapter 5). Children who could not be classified into 
definite, probable or possible TB were categorized as “No TB”. TST and QFT results were 
not included in the definition of TB disease to prevent incorporation bias. A positive TST 




Data were entered into a Microsoft Access database and were analysed using STATA 

















compare proportions. The Mann-Whitney test was used to assess differences between groups 
when results from continuous variables were not normally distributed.  
 
Ethics approval and participant follow-up 
The study protocol was approved by the University of Cape Town, Faculty of Health 
Sciences Human Research Ethics Committee. Informed consent for study participation was 
obtained from parents or guardian of each child. The research ward clinician managed 
participants utilising the clinical findings and CXR interpretation available at the time of 
admission and discharge. Children diagnosed with TB disease were started on standard TB 
therapy and those with LTBI (defined as those with a household TB contact, TST ≥10mm 
and no other findings) on preventive TB therapy. QFT results were not used for clinical 





TST and QFT results were available for 397/400 (99%) of children, who were included in the 
final analysis for this study. Table 1 shows their demographic and clinical characteristics, 
and the TB disease status according to the study algorithm. TST indurations were <5mm in 
317(80%) of participants, while (72)18% had a TST result ≥10mm. The QFT was positive in 
(68)17% of the participants. Just over a third of the participants reported close contact with an 
adult TB source case. Thirteen children (3.3%) were diagnosed as having TB; and among 




















Table 1: Demographic and clinical profile of participants evaluated (N=397) 
Variable n (%) 
Age median (range), months 23 (9-34) 
Gender n (%)                                     Male  
                                                        Female                                               
206 (52) 
191 (48) 






































CXR findings consistent with TB       Yes                           
No 




                       M.tb. positive(Culture)
b










QFT: QuantiFERON-TB Gold In-Tube; CXR: Chest x-ray; M.tb: Mycobacterium tuberculosis Failure to thrive; 
a
persistent inadequate weight gain or persistent weight loss determined by the research ward clinician on 
review of the Road to Health Card; M.tb. positive (Culture); 
b
There were no smear positive cases TB Disease; 
c
Definite, probable and possible TB 
 
 
Comparison of QFT and TST  
Sixty eight (17%) children had positive QFT results and 72 (18%) had positive TST results 

















QFT results were younger than those with positive or negative results (p<0.05). There was 
excellent agreement between the TST and QFT test results (94%, kappa = 0.79 (95% 
confidence interval (CI) 0.69-0.89); children with indeterminate QFT results excluded) 
(Table 2). There was no difference in age and in the proportions with TB related features 
(cough, household TB contact, failure to thrive) between children with discordant and those 
with concordant test results. Amongst the 145 children with a household TB contact the 
proportion with a positive QFT test result was similar to that with a positive TST result 
(38/145, (26%) in both groups). 
 
 
Table 2: Comparison of TST and QFT results in participants evaluated and by TB 
disease status (N= 397) 













QFT result positive 
(IFN-γ > 0.35/mL) 
57 (79%) 11 (3%) 20 (38%) 48 (14%) 
QFT result negative 13 (18%) 295 (91%) 29 (56%) 279 (81%) 
QFT result 
Indeterminate 
2 (3%) 19 (6%) 3(6%) 18(5%) 
TB Disease
c
: Definite, probable and possible TB; TST: Tuberculin skin test; QFT: QuantiFERON-TB Gold In-Tube 
 
 
Sensitivity and Specificity 
The sensitivity and specificity for detecting M.tb infection in children with TB disease 
(definite, probable or possible TB) were similar for both tests (Table 3). Exclusion of 
children with indeterminate QFT results gave a slight increase in both the sensitivity and 
specificity of QFT. TST sensitivity and specificity were similar regardless of whether a 10 or 
15 mm cut-off was used. The NPVs of TST and QFT results, in all analyses, were 
consistently around 90%. The PPVs of the two tests were low (29% for QFT, 25% for TST). 
This is shown in Table 3. Using a stricter definition of TB disease (definite and probable TB 




















Table 3: Sensitivity, specificity, negative predictive value (NPV) and positive 
predictive value (PPV) of QFT and TST for detecting M.tb infection in children 




















       








35 (22-49) 32 (17-49) 








84 (79-87) 86 (81-89) 
PPV (%) 29 (19-42) 25 (16-37) 25 (15-37) 22 (13-34) 18 (1-29) 19 (10-30) 
NPV (%) 91(87-94) 90 (86-93) 89 (85-92) 94 (90-96) 92 (89-95) 92 (89-95) 
d
After excluding QFT indeterminates (denominator n=376); PPV: Positive predictive value; NPV: negative 
predictive value; TST: Tuberculin skin test; QFT: QuantiFERON-TB Gold In-Tube; CI: confidence interval 
 
 
Factors associated with a positive QFT or TST result 
In univariate and multivariate analyses, children with a household TB contact or with CXR 
abnormalities were more likely to have a positive QFT or TST test result (Tables 4A and 4B). 
Age, gender and the most common symptoms (cough, failure to thrive, fever and wheeze) 





















Table 4A: Association between QFT and TST results and other diagnostic features 
of TB disease: Univariate analysis (Participants with indeterminate QFT results were excluded from this analysis) 

















n 376 68 (18)  70 (19)  
























Gender                 Male 
Female 
198 (53) 























































































  2 (22) 
*3.2 (1.7-6.2) 
1 






















Table 4B: Association between QFT and TST results and other diagnostic features 
of TB disease:-Multivariate analysis (Participants with an indeterminate QFT result were excluded from this 
analysis) 






Adjusted Odds Ratio 
(95% CI) 
Age 1 (0.6-1.8) 1.0 (0.6-1.7) 
Gender 1.1 (0.6-1.9) 1.0 (0.6-1.7) 
Household TB Contact *2.6(1.5-4.6) *2.3 (1.3-4.0) 
Cough >2weeks 1.5(0.6-3.7) 1.2(0.5-2.9) 
Failure to thrive 0.6 (0.3-1.1) 0.7 (0.4-1.3) 
Fever 0.5 (0.1-1.7) 0.8 (0.3-2.4) 
Wheeze 0.8 (0.3-1.9) 0.7 (0.3-1.7) 
CXR abnormalities *4.5(2.2-9.0) *3.4 (1.7-6.8) 
QFT: QuantiFERON –TB-Gold in-Tube; CXR: chest-x-ray; *statistically significant;  
 
 
Quantitative results from the QFT and TST 
Fifty-four children (14%) had IFN-γ levels of QFT that were above the highest standard 
provided for the assay 
31
. Plasma dilutions were therefore necessary, and were then included 
in the analysis of data from all participants. Children with a positive TST result, a household 
TB contact or with TB disease had significantly higher IFN-γ levels, compared with children 
without these features (p<0.001, p=0.01, p=0.01 respectively. Figure 1, Panels A, C, E). 
Similarly, those with a positive QFT result or with TB disease had significantly higher TST 
indurations compared with children without these features (p<0.001, p=0.01 respectively. 
Figure 1; Panels B, F). TST indurations were similar between those with and without a 





















Figure 4: Relationship between absolute IFN- γ levels, measured in plasma from 
the QFT after appropriate dilution: with a positive TST (A), presence of a household contact 
(C) and presence of TB disease (E). The relationship between absolute TST induration and a positive 
QFT (B), presence of a household contact (D), and presence of TB disease (F) are also shown.  






















































































































HHC- Household TB contact; QFT-GIT: QFT. 
Median bars have been excluded because for some median = 0 





















We found similar proportions of children less than 3 years old with suspected TB disease 
who had positive TST and QFT results. Agreement between the tests was excellent. Children 
with indeterminate QFT results were younger than those with positive or negative results. 
The sensitivities and specificities of both tests for detecting M.tb infection in children 
diagnosed with TB disease were similar, and both tests had a low PPV, while the NPV was 
high. As expected absolute QFT IFN-γ levels and TST indurations were significantly higher 
in children with a household TB contact or TB disease.  
 
The level of agreement (kappa = 0.79) between the TST and QFT in our study was 
comparable to that observed in studies conducted in children in India and South Africa, 
which reported kappa scores of 0.73 and 0.78 respectively 
15,22
. Other studies in children 
mainly from low TB incidence countries have reported lower levels of agreement between 
QFT and TST (kappa range 0.5-0.56) 
11, 24, 25, 33-36
. Lower kappa scores have also been 





 and South Africa (0.56) 
25
. The literature thus shows variable performance of IGRAs 
in different populations, and TB incidence settings 
5, 7
. Different levels of concordance 
between the TST and QFT could be due to the inclusion of children of different ages in the 
various studies, different TST cut offs used in the comparisons, differences in the TB disease 
status of the children analysed, variation in BCG vaccination status, and different exposures 
to M.tb and environmental mycobacteria. In our study all children were from the same area, 
all were less than 3 years old, and all had been vaccinated with BCG. The level of agreement 
that we found suggests that TST cross reactivity with BCG in this population may be low, as 
was found in Botswana where TST responses ≥ 10mm were attributed to exposure to M.tb 
and not to BCG cross reactivity 
36
. This is significant for the use of TST in TB vaccine trials 
and research studies conducted in settings similar to ours. 
 
Although very few children in our study were HIV positive, QFT and TST sensitivity for 
M.tb infection (38% and 35%, respectively) was lower than observed in other paediatric 
studies on IGRAs 
15-17, 34- 36
 from both high and low TB incidence countries. These studies 
included older children, and had IGRA sensitivities ranging between 40% and 94%, while 
TST sensitivities ranged between 52% and 100% 
15-17, 34-36

















have been reduced by over-diagnosis of TB since very few cases were bacteriologically 
confirmed. Our observed QFT and TST specificities (82% and 84% respectively) differ from 
those reported by other authors in low and high TB prevalence settings. Detjen et al 
35
 
reported specificities of 100% and 58% respectively, while Bianchi et al 
33 
reported QFT and 
TST specificities of 86% and 87% at (5mm TST cut off). A more recent study conducted in 
Tanzania reported QFT and TST specifities of 90% and 98% respectively in children with TB 




In a study conducted in the same community as ours, T.SPOT TB sensitivity among children 
<5 years old with TB (definite and probable TB) was 40%, and specificity 84% 
16
, 
comparable to our findings. In KwaZulu-Natal, South Africa, Liebesheutz et al 
14
 found a 
higher sensitivity of 83% for the ELISPOT assay, compared with 63% for TST, among 
children <14 years old with TB disease.
 
Other studies in children, mainly from low TB 
incidence countries have also reported QFT sensitivities better than that of the TST 
33, 34, 36
. 
Overall, the literature suggests that IGRAs have a lower sensitivity and specificity for M.tb 
infection in high compared to low TB incidence settings 
8, 10
.The low sensitivity that we 
observed supports reports that IGRAs may perform differently in younger children compared 
with older children, in agreement with reported indings of lower IFN-γ production in 
younger children and a positive correlation between age and IFN-γ production 
37, 38
. The 
younger age of children with indeterminate QFT results is also consistent with findings that 




Kampmann et al 
35 
and Bamford et al 
11
 showed that combining TST and IGRA results 
improves sensitivity in individuals with TB disease. This approach would not have been 
useful in our population, as only 2 of the 49 TB cases (excluding 3 cases with indeterminate 
QFT) had discordant results.  
 
It was not surprising that both the TST and QFT were significantly associated with a 
household TB contact, as both indicate exposure to M.tb. The equally strong association of 
both tests with CXR abnormalities suggests that the QFT does not provide additional 
advantage above the TST as a diagnostic aid for TB disease in young children in this setting. 
Age was not associated with either test, probably because we had a limited variation in age 

















the TB related clinical features investigated, probably because these clinical features are not 
specific to TB disease in young children. 
 
Quantitative analysis 
We found a large proportion of participants with IFN-γ levels above the highest standard 
results. This may indicate that if quantitative levels are to be used in a study setting, plasma 
dilutions are required for reliable results in similar settings. This has been confirmed in 
dilution studies conducted on blood samples from adolescents (South African tuberculosis 
Vaccine Initiative (SATVI), unpublished data).  
 
Strengthens and limitations 
This study conducted intensive investigations for TB disease on a large number of children 
and used well defined diagnostic criteria to classify TB cases. Serial dilutions were performed 
to precisely estimate quantitative IFN- γ levels. However there were some limitations. A 
small proportion of children had active TB (13%) and an even smaller proportion had 
bacteriologically confirmed disease (1%). Therefore, test sensitivities were estimated with 
relatively poor precision. There were no data on duration of exposure or smear status of adult 
contacts; hence we could not analyze household exposure in detail. Despite rigorous 
diagnostic criteria, use of radiological and clinical features to determine TB diagnosis could 
have resulted in over-diagnosis of TB (probable and possible TB) and underestimation of the 
sensitivity of both tests. However, since sensitivity remained largely unchanged with a 
stricter TB definition (definite and probable TB only), over-diagnosis is unlikely to have 
influenced results markedly. The predictive values should be interpreted with caution because 
they are affected by prior probabilities which were not determined in this study. Follow-up 
data on all children are unavailable, since no follow-up testing was done. Only 2 children 




This study showed excellent agreement between the TST and the QFT in this population of 
BCG vaccinated children in a high TB incidence setting. Both tests had low sensitivity, a 
reasonably high specificity for M.tb infection, and a high NPV. Comparable rates of test 
result positivity suggests that in HIV negative children younger than 3 years old, in high TB 
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Chapter 5: Radiographic abnormalities among young children 
detected through active TB case-finding who are investigated for 




Background: Chest radiographic findings described among children with tuberculosis (TB) 
in high burden countries reflect severe, uncontained pulmonary disease. Our hypothesis was 
that this radiographic phenotype is related to passive case detection and late presentation. 
Objectives: To describe chest radiographic features in young children with suspected 
pulmonary TB, in active case-finding in a high TB burden setting, and to identify the key 
clinical features associated with these radiographic phenotypes.  
Methodology: Chest radiographic abnormalities in young children with suspected pulmonary 
TB, in an active TB case-finding study were analysed. TB suspects based on contact history 
or compatible symptoms underwent standardized clinical, radiographic, and microbiological 
testing. The radiographs were independently reviewed for pre-defined abnormalities by three 
paediatric radiologists who were blinded to clinical information.  
Results: Nine hundred and forty-seven chest radiographs were reviewed. Hilar 
lymphadenopathy and parenchymal consolidation were isolated radiographic findings in 51 
(5.4%) and 44 (4.6%) radiographs, respectively, and occurred together in 17 (1.8%). 
Cavitation, miliary nodules, and pleural disease were not demonstrated. Lymphadenopathy 
and consolidation, occurring in combination, was associated with failure to thrive (OR 3.74; 
95%CI 1.33-10.48) and a positive culture for Mycobacterium tuberculosis (M.tb) (OR 10.33; 
95% CI 1.78-60.0). 
Conclusion: The radiographic features demonstrated by active TB case-finding in this 
population largely reflect uncomplicated primary complex TB with a small proportion of 
uncontained parenchymal disease. This mild radiographic disease phenotype may reflect 
radiological changes associated only with M.tb infection, and not TB disease. Growth failure, 
rather than persistent cough, was the clinical hallmark of uncontained pulmonary TB in 
young children in this setting. Infant TB vaccine trials, other preventive trials, and TB control 
programmes adopting active case-finding should prioritize growth failure as a sentinel 




















Chest radiographs (CXRs) play a definitive role in the diagnosis of childhood pulmonary 
tuberculosis (TB), since bacterial confirmation occurs in less than 40% of cases in children
 1-
6
. Diagnosis is therefore usually based on a combination of history of contact with an 
infectious source case, compatible symptoms, a positive tuberculin skin test (TST) or 
Mycobacterium tuberculosis (M.tb) specific interferon gamma release assay (IGRA), and 
specific changes on CXR 
1-8
. Although the interpretation of CXR findings in children with 
pulmonary TB is variable, intrathoracic lymph node, parenchymal, and extra-thoracic 
radiographic abnormalities compatible with TB have been well-described
 5, 9, 10
. Published 
descriptions of CXR findings among children with pulmonary TB in high burden countries 
have generally reflected severe disease, which is characterized by complicated intrathoracic 




Our hypothesis was that this radiographic profile is a function of passive case detection, with 
delayed presentation in older children, and that active case-finding (ACF) would result in a 
different profile. This is based on studies that have shown that in ACF settings TB disease 
tends to be mild, is detected earlier, in younger children, and that the rate of bacteriologic 




There is limited data on the chest radiographic phenotype in ACF settings in young children 
in developing countries. This is because TB cases including those in children have largely 
been detected passively
 
in these countries 
16, 17
. The description and understanding of CXR 
findings in ACF in young children in high TB burden countries is essential to inform the 
development of case definitions for research settings, since ACF is likely to be integral to 
clinical trials of new TB vaccines, drugs, and other interventions against TB conducted in 
these settings.  
 
The objectives of this study were to describe CXR abnormalities in young children with 
suspected pulmonary TB, detected through ACF in a high TB incidence setting, and to 




















Setting and participants 
The CXRs analysed in this study were obtained from participants enrolled in a study 
comparing two ACF strategies that is described in Chapter 3. CXRs were taken shortly after 
determining that a child had suspected TB, and hence a temporal association with 
symptomatology was assumed.  
 
 
Reading of chest radiographs 
The original CXR films were scanned using a high-resolution flatbed scanner (Epson E1680-
PRO), saved as jpeg images, and reviewed independently by three paediatric radiologists 
experienced in childhood TB. The radiologists were blinded to clinical information. Findings 
were recorded on a standardized reading and recording form (Appendix 2). The reviewers 
reported on whether any of the following abnormalities were “definitely present”, “definitely 
absent”, “possibly present”, or “not visible” (due to technical reasons);  
- intrathoracic lymphadenopathy (hilar or paratracheal), 
- parenchymal consolidation,  
- pleural abnormalities (pleural thickening or pleural effusion),  
- miliary disease,  
- cavitation  
 




Data were captured in a Microsoft Access database and analysed using STATA version 10.0 
(Stata Corp College Station, Texas, USA). Abnormalities were regarded as “present” when 
recorded as “definitely present” by at least two of the three reviewers. The Pearson Chi-
square test and the Fisher’s test (1-sided) were used to compare clinical features between 
children with and without CXR abnormalities in univariate analysis. The Mann-Whitney and 
the Kruskal-Wallis tests were used to compare groups with continuous data that were not 
normally distributed. Forward, nested logistic regression was used in multivariate analysis of 

















confidence interval (CI) did not cross 1. Sensitivities, specificities and predictive values of 




Nine hundred and seventy (970) CXRs were obtained from 880 children identified as TB 
suspects and investigated for TB, from a cohort of 4,786 children under active surveillance 
for pulmonary TB
 17
. Twenty-three radiographs that were not reviewed by at least two 
reviewers were excluded from further analysis. The remaining 947 radiographs, obtained 
from 862 children, were analysed. Eighty-three children were evaluated for TB on more than 
one occasion during the study follow-up period, therefore 81 children had two CXRs and two 
children had three CXRs each. The median age at the time of chest radiography was 13.2 
months (IQR 7.8–21.0 months).  
 
Lymphadenopathy and parenchymal consolidation were the most frequent CXR 
abnormalities detected by all reviewers (Figure 1). Lung tissue nodules, miliary TB, pleural 
disease, and cavities were detected in a very small number of radiographs by individual 
reviewers (less than 1%, Figure 1), with no two reviewers identifying these features on the 
same CXR.  
 
Figure 1: Radiographic findings in 947 chest radiographs from child TB suspects 





















































































Using the two-out-of-three reviewer agreement criteria for classification of radiographic 
features as definitely present, abnormalities were detected in a total of 112 (11.8%) 
radiographs. Lymphadenopathy was detected in 68 (7.5%) and parenchymal consolidation in 
61 (6.4%). Isolated lymphadenopathy was detected in 51(5.4%), isolated parenchymal 
consolidation in 44 (4.6%), and lymphadenopathy and parenchymal consolidation occurred 
together in 17 (1.8 %) radiographs. There was no difference in ages between children who 
presented with isolated lymphadenopathy, isolated parenchymal consolidation, or 
lymphadenopathy and parenchymal consolidation in combination (p=0.82). Six children 
(0.7%) were HIV infected, of whom five had normal CXRs, and one had isolated 
lymphadenopathy. 
 
Table 1 shows the clinical, epidemiological and microbiological features of TB in children 
with or without radiographic abnormalities. There was no significant difference in the 
proportion of symptoms, signs, and positive culture for M.tb in the two groups, except that 
children with CXR abnormalities more often reported history of contact with a TB source 
case, or were more likely to have a positive TST. There was no difference in age between the 



















Table 1: Association between clinical, epidemiological and microbiological 
features of TB disease and chest radiographic abnormalities (N= 947 chest 
radiographs)  
Clinical feature CXR abnormalities 






































2.4 (1.58-3.64) *<0.001 
a















CXR-Chest radiograph, Y-Yes, N-No, FTT-failure to thrive, TST-tuberculin skin test, M.tb-Mycobacterium tuberculosis, OR-odds ratio, CI-
confidence interval, aThere were no smear positive cases, *statistically significant 
 
Among the 68 radiographs with lymphadenopathy, 8 (12%) showed compression of the 
airway. Four (50%) of the 8 children with radiological evidence of airway compression 
reported a history of wheezing for more than two weeks. Three of these four children also 
reported cough for more than two weeks. 
 
Of the 947 radiographs analysed, 73(8%) were deemed unreadable by Reviewer 1; five 
(0.5%) deemed unreadable by Reviewer 2; and three (0.3%) were deemed unreadable by 
Reviewer 3. For radiographs that were read, agreement between reviewer pairs for 
radiographic findings ranged from 82%-90%; and weighted kappa scores for positive 
detection of lymphadenopathy or consolidation ranged between 0.17-0.32 (Table 2). The 
average weighted kappa scores for the detection of lymphadenopathy and consolidation were 



















Table 2: Detection of lymphadenopathy and parenchymal consolidation: 
Agreement between reviewer pairs 
 Lymphadenopathy  Parenchymal consolidation 
 Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 1 Reviewer 2 Reviewer 3 
Reviewer 1  82% 91% 
 
 94% 96% 




















Percentage agreement between reviewer pairs is presented above the diagonal spaces for each category; weighted kappa scores are 
presented below the diagonal spaces for each category. 
 
Table 3A shows the association between clinical, epidemiological and microbiological 
features of TB with radiographic phenotypes in univariate analysis. History of a contact with 
a TB source was associated with isolated parenchymal consolidation (a negative association). 
A positive TST was associated with isolated lymphadenopathy. Failure to thrive, and a 
positive culture for M.tb, was associated with lymphadenopathy and parenchymal 
consolidation occurring in combination, as was the combined presence of a positive TST, 
cough for more than 2 weeks, and failure to thrive. Associations between individual clinical 
features and radiographic abnormalities that were statistically significant in univariate 



















Table 3A: Association between clinical, epidemiological and microbiological 
features of TB disease with individual or combined chest radiograph 





















































































































































































































































































cough >2 weeks 























































Y-Yes, N-No, FTT-failure to thrive, TST-tuberculin skin test, OR-odds ratio, CI-confidence interval, TST ≥10mm, M.tb-Mycobacterium 





















Table 3B: Association between clinical, epidemiological and microbiological 
features of TB disease with individual or combined chest radiograph 




























0.99 (0.54-1.81) 0.97 1.06 (0.57-1.99) 0.85 1.60 (0.59-4.33) 0.35 
FTT  1.21 (0.67-2.19) 0.52 1.16 (0.62-2.18) 0.64 3.74 (1.33-10.48) 0.12 
b
TB contact  
 










0.68 (0.08-5.44) 0.71 2.05 (0.26-16.35) 0.50 10.33(1.78-60.0) *0.009 
       
FTT-failure to thrive, TST-tuberculin skin test, OR-Odds Ratio, M.tb-Mycobacterium tuberculosis, athere were no smear positive cases, bThe 
variables TB contact and TST were not included together in the models because of collinearity; TB contact was included in the model 
testing associations with parenchymal consolidation since it showed a significant association in univariate analysis; the c TST was included 
in the other two models. *statistically significant 
 
 
Individual TB symptoms and signs had low positive predictive values (PPVs), high negative 
predictive values (NPVs), low sensitivities and high specificities for each of the radiographic 
phenotypes, despite the statistically significant associations noted above (Table 4). History of 
contact with a TB source case demonstrated 73% sensitivity for isolated lymphadenopathy, 
and failure to thrive 65% sensitivity for combined radiographic pathology. The combined 
presence of a positive TST, cough for more than two weeks, and failure to thrive, had low 





















Table 4: Sensitivity, specificity and predictive values of clinical, epidemiological 




































































































             
Cough >2 
weeks  
35 63 5 95 39 63 5 96 47 64 2 99 
 
FTT 34 66 3 91 39 64 5 96 65 66 3 99 
TB contact  73 35 6 96 50 34 4 93 53 35 1 98 
 























6 97 15 95 - 97 - 95 24 97 14 99 
TST-Tuberculin skin test, M.tb-Mycobacterium tuberculosis, FTT-failure to thrive, aM.tb-Mycobacterium tuberculosis, ‡there were no 




Uncomplicated intrathoracic lymphadenopathy and parenchymal consolidation were the most 
frequent chest radiographic findings among very young children with suspected TB, in ACF 
in a high TB burden setting. Isolated hilar or paratracheal lymphadenopathy, which are 
consistent with early or contained primary complex TB, occurred three times more often than 
the combination of intrathoracic lymphadenopathy and parenchymal consolidation, which are 
suggestive of progressive or uncontained pulmonary TB. Radiographic evidence of pleural 


















A positive TST was significantly associated with isolated lymphadenopathy, as might be 
expected, and failure to thrive and a positive culture for M.tb were each significantly 
associated with lymphadenopathy and parenchymal consolidation occurring in combination. 
However, persistent cough, a hallmark of childhood TB diagnosis among older children, was 
not associated with radiographic evidence of intrathoracic lymphadenopathy or parenchymal 
consolidation, alone or in combination, in this age group and study setting. Persistent wheeze 
was reported in a small number of children who had radiographic evidence of intrathoracic 
airway compression. 
 
The most common radiographic phenotype in this analysis, isolated intrathoracic 
lymphadenopathy, is frequently the only radiographic finding in children identified for 
evaluation for TB through contact tracing and screening
 13
. We found isolated 
lymphadenopathy and isolated parenchymal consolidation in similar proportions, whereas a 
study of actively detected child contacts of adult TB cases in Cape Town, did not report 
isolated parenchymal consolidation, but a greater proportion (2.5% compared to 1.8% in our 
study) of the combination of lymphadenopathy and consolidation
 13
. This difference could be 
due to the relatively broad screening criteria that we used to identify TB suspects. This might 
have also identified children with other respiratory infections apart from TB for investigation. 
This is consistent with our observed negative association of TB contact history and isolated 
parenchymal consolidation, suggesting that this radiographic feature is frequently unrelated 
to TB disease in this age group and study setting. Conversely, since we conducted intensive 
case-finding, it is also likely that many children in our study were investigated while they 
were in the early stages of M.tb infection and disease, before development of uncontained, 
progressive parenchymal changes. This may explain the lower proportion of chest 
radiographs with both lymphadenopathy and parenchymal consolidation in our study.  
 
A positive TST was the only individual feature significantly associated with isolated 
lymphadenopathy. This is consistent with early radiographic changes after infection with 
M.tb. However, it is not possible to determine for any individual child whether isolated 
intrathoracic lymphadenopathy is a manifestation of early TB disease that has not yet 
progressed into the parenchyma, static lymphadenopathy that will remain contained, or 
transient primary complex TB that will spontaneously resolve, as has been described in the 




















Our observed association between a positive culture for M.tb and failure to thrive with 
lymphadenopathy and parenchymal consolidation occurring in combination suggests that 
growth failure should be prioritized in efforts to detect TB cases early. The observed lack of 
an association between persistent cough and combined lymphadenopathy and parenchymal 
consolidation suggests that persistent cough could be a non-specific sentinel symptom for 
radiographic TB disease in this age group. However, it is possible that a more detailed 
characterisation of the nature of the cough could have yielded different results, since a 
persistent non-remitting cough for longer than two weeks is a sensitive indicator of TB 




The sensitivities and PPVs of TB symptoms and signs for CXR pathology were low to 
moderate. However, a positive culture for M.tb and the combined presence of a positive TST, 
cough for greater two weeks, and failure to thrive, had ≥97% specificity for all three 
radiographic phenotypes. This suggests that diagnostic criteria incorporating this combination 
of clinical features might be useful in excluding TB in young children with respiratory or 
constitutional illnesses other than TB, who are identified as suspects in ACF settings. 
 
The frequency of detecting radiographic features of TB varied considerably between expert 
reviewers, as has been shown previously
 18
. The average weighted kappa score of 0.27 for the 
detection of lymphadenopathy was lower than that reported among hospitalized children 
investigated for pulmonary TB, where the average weighted kappa was 0.33
 18
. The lower 
level of agreement may be due to the fact that our study was community based, and that we 
conducted intensive surveillance for TB suspects. Therefore, we would expect that a large 
proportion of children with TB would have had early, mild disease, and hence, less clearly 





Although this study had a large sample size, which allows evaluation of uncommon events, 
there were some limitations. First, follow-up CXRs were not performed; hence, we are unable 
to assess the evolution of radiographic features or response to TB treatment in children who 
received preventive or curative TB therapy on discharge from the research ward. Secondly, 
the CXR films were scanned and read as digital jpeg images, which might have affected 
image quality, although we do not regard this as significant. Thirdly, we detected few 

















spectrum, but this limited our ability to examine associations with M.tb culture positivity. 
Lastly, the criteria used to define the presence of CXR abnormalities (agreement by two-out-
of-three reviewers) might be considered overly stringent, given the variability of CXR 
interpretation
 5, 18
. However, we believe that this specific approach is appropriate, given the 




The radiographic features demonstrated by active TB case-finding in this study population 
largely reflect uncomplicated primary complex TB with a small proportion of uncontained 
parenchymal disease. This mild radiographic disease phenotype may reflect radiological 
changes associated only with M.tb infection, and not TB disease. Growth failure, rather than 
persistent cough, appears to be the clinical hallmark of uncontained pulmonary TB in young 
children in this setting. Infant TB vaccine trials, other preventive trials, and TB control 
programmes adopting active case-finding should prioritize growth failure as a sentinel 




This chapter was written by Dr S. Moyo under the guidance of Dr S. Verver, Associate 
Professor M. Hatherill and Professor G. Hussey. S. Moyo managed the study and analysed 
data under the supervision of Associate Professor M. Hatherill, Dr S. Verver and Professor G. 
Hussey. The study was designed by S. Moyo, G. Hussey, S. Verver, L. Geiter and A. 
Hawkridge. L. Workman and H. Mulenga managed the study database. M. Tameris, H. 
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Chapter 6: Serious adverse events in young children enrolled in TB 




Setting: A tuberculosis (TB) vaccine trial site in a rural area in South Africa. 
Objectives: To determine the nature and rate of serious adverse events, defined as hospital 
admissions and deaths, and the proportion due to TB in young children enrolled in TB 
vaccine trials. 
Methodology: Hospital admission and mortality data from two TB vaccine trials (Cohort 1 
(2001-2006) and Cohort 2 (2005-2008)), that were conducted in children aged 0-2 years were 
analysed. 
Results: In Cohort 1, 2895 hospital admissions were recorded from a cohort of 11680 
children enrolled, giving a 19% hospitalisation rate over two years. In Cohort 2, 718 
admissions were recorded from a cohort of 4786 infants enrolled, giving a hospitalisation rate 
of 15% over two years, (p=0.008). There was a broad spectrum of morbidity which was 
dominated by respiratory tract infections (33% Cohort 1, 31% Cohort 2), and diarrhoeal 
disease (32% Cohort 1; 24% Cohort 2). TB accounted for 4% and 6% of admissions in 
Cohorts 1 and 2 respectively (p=0.04). There were few HIV related illnesses and these were 
associated with TB (Cohort 1 OR 4.13, p< 0.05; Cohort 2 OR 84, p<0.0001). Mortality was 
also predominantly due to respiratory tract infections and diarrhoeal disease, with a small 
proportion of deaths due to TB, 0.3% in Cohort 1 and 1% in Cohort 2. Specific causes of 
mortality could not be assigned to 18% and 51% of deaths in Cohorts 1 and 2 respectively. 
Conclusion: Serious adverse events in these trials were dominated by respiratory tract 
infections and diarrhoeal disease. Although the overall proportions were low, hospital 
admissions and deaths due to TB were significant contributors to serious adverse events in 





















Clinical trials that evaluate new products are required to identify and report on the occurrence 
of trial endpoints and serious adverse events (SAEs) occurring among trial participants
1, 2, 3, 4
. 
A serious adverse event is defined as “any untoward or unfavourable medical occurrence in a 
clinical trial participant that is life threatening, results in death, hospitalisation, disability, 
congenital anomaly, or requirement of an intervention to prevent permanent impairment or 
damage” 
3, 4





Hospital admissions and deaths among trial participants are important serious adverse event 
in clinical trials of TB new vaccines that are conducted in young children in developing 
countries. In these settings the burden of morbidity and mortality in this age group is 
generally high 
6-9
. Respiratory tract infections (RTIs), diarrhoea and malnutrition are major 
contributors to this burden 
6-9
. This is significant because RTIs commonly occur together with 
TB and because TB may be undetected in the children diagnosed with RTIs in high TB 
burden settings, while malnutrition increases the risk of developing TB 
10-15
. The detection of 
all TB cases is important in TB vaccine trials because TB disease is the current endpoint for 
these trials. Secondly, hospitalisation and mortality data are important for detecting events 
related to or caused by the investigational vaccine.  
 
Causes of mortality among children enrolled in TB vaccine trials at a rural TB vaccine trial 
site in South Africa have previously been reported 
16, 17
. Pneumonia, gastroenteritis and 
septicaemia were the main causes of mortality
16, 17




















Figure 1: Immediate causes of death assigned by the record review method 
(CR/VA) and by death certificates (DC) Moyo S et al, Determining cause of mortality in children 
enrolled in a vaccine trial in a rural area in the Western Cape province of South Africa. Journal of Pediatrics 
and Child health 2007; 43; 178-183. 
 
 
In this chapter our objectives were to determine the nature and rate of serious adverse events, 
(defined as hospital admissions and mortality), and the proportion due to TB in young 
children enrolled in TB vaccine trials at a vaccine trial site in South Africa. This analysis also 
provides baseline data for comparison with findings in future trials of novel TB vaccines to 




We analysed hospital admission and mortality data from two trials (Cohort 1 and Cohort 2) 
that were conducted at the South African Tuberculosis Vaccine Initiative (SATVI) trial site in 
the Cape Winelands district of South Africa over the period 2001 to 2008. The first trial 
(Cohort 1) was conducted between 2001 and 2006, while the second (Cohort 2) was 
conducted between 2005 and 2008. In 2007, the estimated population in the Cape Winelands 
district was 327 822 people 
18
. The district is among the 20% least deprived districts in South 
Africa with a poverty rate of 21% in 2007 
19
. The 2007 infant mortality and under 5 mortality 




















Cohort 1- Efficacy of percutaneous versus intradermal Bacille Calmette Guérin (BCG) 
in the prevention of tuberculosis in South African infants: randomised trial (2001-2006) 
This was a randomised controlled trial comparing the efficacy of the percutaneous and 
intradermal routes of administering the Bacille Calmette Guérin (BCG) vaccine in preventing 
TB in children aged 0-2 years 
20
. Infants were randomized at birth to percutaneous or 
intradermal administration of BCG. Serious adverse events were detected by an extensive 
surveillance system developed at the trial site. Surveillance entailed i) a study visit at age 3 
months where symptom screening for TB was conducted, ii) review of hospital admission, 
radiology department, and clinic attendance records, and iii) review of death certificates and 
conducting verbal autopsy interviews in case of deaths (where consent was granted by the 
family). The surveillance system also detected children with suspected TB. TB suspects 
underwent standardized evaluation for TB disease in a dedicated study research ward. These 
investigations are as described in Chapter 3. [A medical history and examination were 
performed by a clinician and the following investigations conducted: CXR (anterolateral and 
antero-posterior films), tuberculin skin test (TST) by the Mantoux method, Human 
Immunodeficiency Virus (HIV) testing (with parental/legal guardian consent), paired early 
morning gastric washing (GW) and induced sputum (IS) specimen collection on two 
consecutive days. Smear microscopy (auramine fluorescent microscopy) and culture for M.tb 
(Mycobacterial Growth Indicator Tube (MGIT) 960) were performed on all GW and IS 
specimens. Cultures were incubated for at least 6 weeks. Positive cultures underwent 
speciation to exclude non-tuberculous mycobacteria. The TST was read 48-72 hours after 
administration]. 
 
Personal identifiers:-names, date of birth and residential address, were used to identify study 
participants from hospital admission and clinic attendance lists in the four hospitals and 23 
clinics in the study area. These lists were perused manually once every week to identify new 
entries. Medical records of participants who had been hospitalised were then obtained. 
Mortality records at the regional Health Office were also perused weekly to identify study 
participants who might have died, and attempts were then made to obtain all available 
medical records including death certificates. Where consent was given, verbal autopsy 
interviews were conducted with the family members of the deceased participant, to obtain 

















certificates and verbal autopsy interview records were reviewed by medical officers to 
determine and document the discharge diagnoses and causes of death.  
 
Cohort 2- Tuberculosis case finding for vaccine trials in young children in high-
incidence settings: a randomised trial (2005-2008) 
This was a randomised trial that compared two active case-finding (ACF) methods on TB 
case accrual and disease severity in BCG vaccinated children aged 0-2 years 
17
. (This study is 
described in Chapter 3). Participants were randomised to three monthly home visits for TB 
symptom screening and clinic and hospital admission record surveillance, or to clinic and 
hospital admission record surveillance only. Study participants were identified from hospital, 
clinic attendance lists, and from mortality records as was described for Cohort 1. All medical 
records, death certificates and verbal autopsy interview records were reviewed by medical 
officers as was described for Cohort 1. Children with suspected TB were also investigated as 
for Cohort 1.  
 
Data were captured into a Microsoft access database, and analysed using STATA version 11. 
In both studies hospital admissions and mortality up to the age of 24 months were analysed. 
Diagnoses and causes of death were grouped into main disease categories that are common in 







In Cohort 1, 2895 hospital admissions were recorded for 2186 children from a cohort of 
11680 children who were enrolled, giving a 19% hospitalisation rate over two years. The 
median age at hospitalisation was 9 months (IQR 5-15 months). In Cohort 2, 718 admissions 
were recorded for 604 children from a cohort of 4786 infants, giving a hospitalisation rate of 
15% over two years, which was significantly lower than that for Cohort 1 (p=0.008). The 
median age at hospitalisation of 9 months (IQR 4-16 months) in Cohort 2 was similar to that 
observed for Cohort 1. 
 
Table 1 shows the number of admissions per child and the total number of hospital 

















of children were hospitalised more than once while in Cohort 2 this proportion was much  




















Table 1: Hospital admissions 
 Cohort 1 (N=11680) 
Period 2001-2006 






























1 1691 77 1691 510 84 510 
2 354 16 708 78 13 156 
3 98 5 294 13 2 39 
4 27 1 108 2 0.3 8 
5 11 0.5 55 1 0.2 5 
6 1 0.05 6    
7 1 0.05 7    
8 1 0.05 8    
9 2 0.09 18    
 
 
In both cohorts the hospitalisation rate peaked in the 6-12 month age category before 
declining in the older ager categories (Table 2). The hospitalisation rate was significantly 
greater in Cohort 2 in all age categories beyond the first month of life.  
 
Table 2: Hospital admissions by age category  








































































































































<1 11680 205 39 1.8% 4786 80 17 1.7% 0.7 
1-<6 11641 718 74 6.2% 4769 165 44 3.5% <0.0001* 
6-<12 11567 868 37 7.5% 4725 181 34 3.8% <0.0001* 
12-<18 11530 627 23 5.4% 4691 159 19 3.4% <0.0001* 





















The morbidity profile was broad and generally similar in the two cohorts, as shown in Table 
3 (Statistical comparison of all the variables in Table 3 are presented in Appendix 1). In both 
cohorts RTIs (33% Cohort 1; 31% Cohort 2) and diarrhoeal disease (32% Cohort 1; 24% 
Cohort 2), were the most frequent conditions, and were followed by admissions for 
pulmonary TB. There were only a few admissions for tuberculous meningitis; two (0.07%) in 
Cohort 1 and three (0.4%) in Cohort 2.  
 
Table 3: Hospital admissions morbidity profile 
  Cohort 1 N= 2895 Cohort 2 N=718 
Diagnosis n % n % 
Respiratory tract infections (infections of the upper and lower respiratory 
tract), excludes pulmonary tuberculosis 
954 33.0 223 31.1 
Diarrhoeal disease (includes the term gastroenteritis, and diarrhoea and 
vomiting) 
926 32.0 175 24.4 
TB (pulmonary tuberculosis) 128 4.4 45 6.3 
Malnutrition (includes marasmus and kwashiorkor) 88 3.0 11 1.5 
Jaundice 60 2.1 16 2.2 
Meningitis (viral, bacterial, unspecified, includes tuberculous meningitis) 53 1.8 9 1.3 
Perinatal conditions and prematurity 49 1.7 7 1.0 
Convulsions (includes, epilepsy) 49 1.7 6 0.8 
Injuries (includes fractures, head injuries and injuries due to motor vehicle 
accidents 
47 1.6 18 2.5 
Febrile convulsions and pyrexia if unknown origin 40 1.4 12.0 1.7 
Renal conditions (includes infections) 35 1.2 6 0.8 
Wheezing (unspecified) 35 1.2 0 0.0 
Burns (hot water and fire burns) 33 1.1 6 0.8 
HIV related illnesses (included cases with  confirmed HIV infection) 32 1.1 6 0.8 
Congenital conditions  31 1.1  0  0.00 
Otitis media 32 1.1 7 1.0 
Sepsis (generalised bacterial infection including meningococcemia) 31 1.1 3 0.4 
Poisoning (ingestion of hazardous material such  including paraffin) 30 1.0 10 1.4 
Abscess(includes cellulitis and empyema) 25 0.9 8 1.1 
Dermatological conditions 20 0.7 6 0.8 
Minor surgical procedures (includes circumcision) 15 0.5 10 1.4 
Asthma  10 0.3 16 2.2 
Eye conditions (includes infections) 9 0.3 3 0.4 
Other (condition or symptoms and signs not included in the conditions 
above) 
51 1.8 36 5.0 



















Table 4 compares the proportions of hospital admissions for selected conditions in the two 
cohorts. The proportion of admissions for diarrhoeal disease was significantly lower in 
Cohort 2 compared to Cohort 1. There were significantly more admissions for TB in Cohort 
2. In Cohort 1, there were 32 (1.1%) hospitalisations for HIV related illnesses, while there 
were six (0.8%) in Cohort 2. Eleven percent of admissions Cohort 2 could not be assigned a 
specific diagnosis. This was significantly greater than the corresponding proportion (3.9%) 
observed for Cohort 1 (p=0.003).  
 
 
Table 4: Comparison of proportions of hospital admissions for selected conditions 
  Cohort 1 N=2895 Cohort 2 N=718 p value 
Diagnosis n % n %   
Respiratory tract infections (infections of the 
upper and lower respiratory tract), excludes 
pulmonary tuberculosis 
 
954 33.0 223 31.1 0.33 
Diarrhoeal disease (includes the term 
gastroenteritis, and diarrhoea and vomiting) 
 
926 32.0 175 24.4 0.0001*  
TB (pulmonary tuberculosis) 128 4.4 45 6.3 0.03* 
Malnutrition (includes marasmus and 
kwashiorkor) 
88 3.0 11 1.5 0.03* 
Jaundice 60 2.1 16 2.2 0.79 
Meningitis (viral, bacterial, unspecified, includes 
tuberculous meningitis 
53 1.8 9 1.3 0.29 
Perinatal conditions and prematurity 49 1.7 7 1.0 0.16 
HIV related illnesses (included cases with  
confirmed HIV infection) 
32 1.1 6 0.8 0.48 
Other (condition or symptoms and signs not 
included in the conditions above) 
51 1.8 36 5.0 <0.0001* 
 
 
Hospital admissions by age category 
The age specific morbidity profile was similar in the two cohorts (Figure 2 and Figure 3). In 
both cohorts, in the first month of life, jaundice (29.3% Cohort 1; 20.0% Cohort 2; p= 0.1) 
and perinatal conditions (23.9% Cohort 1; 8.8% Cohort 2; p=0.004) were the predominant 
serious adverse events. In the oldest age category, RTIs (35.7% Cohort 1; 22.6% Cohort 2; 
p=0.001) and diarrhoeal disease (18.8% Cohort 1; 17.3% Cohort 2; p= 0.7) were the most 
frequent conditions closely followed by pulmonary TB (9.4%. Cohort 1; 6.8% Cohort 2; p= 
























Figure 5: Admissions for selected conditions by age category: Cohort 2 
RTI- respiratory tract infections 




Causes of mortality in these trials have previously been reported 
16, 17
. The overall mortality 
rate in Cohort 1 was 1.6% over 2 years, and was 2.5% over 2 years in Cohort 2 (p<0.0001). 
The causes of mortality are shown in Table 5. RTIs and diarrhoea were the leading causes of 
mortality in both cohorts. The proportion of TB deaths was very small, and there was no 

















































































be assigned specific causes; the corresponding proportion was much greater in Cohort 2, 51% 
(p=<0.0001).  
 
Table 5: Mortality profile  
Cause of death Cohort 1 
n (%) 
Cohort 2  
n (%) 
P value 
Respiratory tract infections 50 (26.9) 16 (13.4) 0.005* 
Diarrhoeal disease 38 (20.4 14 (11.8) 0.05 
Septicaemia 28 (15.1) 6 (5) 0.006* 
Tuberculosis 5 (2.7) 1 (0.8) 0.2  
Prematurity 4 (2.2) 4 (3.3) 0.6 
Malnutrition 0 4 (3.3) 0 
Meningitis 0 2 (0.02) 0 
HIV related illnesses 2(1.1) 1 (0.8) 0.8 
Trauma 6 (3.2) 5 (4.2) 0.6  
Unknown/ ill-defined 35 (18.8) 61 (51.3) <0.0001* 
Other 18 (9.7) 5 (4.2) 0.08  




The morbidity and mortality profile at this trial site was dominated by RTIs and diarrhoeal 
disease. Although the overall proportions were relatively low, hospitalisations for pulmonary 
TB were among the most frequ nt serious adverse events. A significant proportion of 
admissions were for unknown or unspecified conditions in Cohort 2. Admissions peaked in 
the 6-12 month age category. The proportion of deaths due to TB was very low. In both 
cohorts a large proportion of deaths could not be assigned specific causes of death (18% 
Cohort 1; 51% in Cohort 2). 
 
The morbidity and mortality burden and profile in both studies reflects that observed in the 
broader study area, and that which is commonly observed in similar settings in developing 
countries
 6-9, 18
. RTIs and diarrhoeal disease were the leading causes of mortality among 
audited deaths in South African hospitals, in children aged 0-18 years between 2005 and 
2009 
21
. The majority of these deaths occurred in children less than 5 years old
 21
. Other 
vaccine trials conducted in Africa have also reported morbidity and mortality profiles 

















conducted in Soweto, 66% of deaths were due to pneumonia and bronchiolitis, and 9% due to 
gastroenteritis
 22
. In another pneumococcal conjugate vaccine trial conducted in rural Gambia, 
pneumonia was a leading cause of hospitalisations 
23
. Therefore our findings demonstrate and 
confirm the profiles that are likely to be observed in clinical trials of new TB vaccines 





The proportion of hospital admissions for pulmonary TB was relatively low (4% in Cohort 1 
and 6% in Cohort 2). This suggests that there were few cases of severe TB that required 
hospitalisation among trial participants. This could reflect the success of the surveillance 
system in detecting TB suspects for evaluation and management in the study research ward. 
(However, it is noted that in Cohort 2, 23 participants were missed by the surveillance system 
and diagnosed with TB outside the research ward, (Chapter 3)). It also demonstrates the 
impact of ACF on the severity of TB disease; ACF has been shown to detect TB cases early 




Although RTIs are common in young children in settings similar to ours, it is however 
possible that some children who were diagnosed with RTIs could have had pulmonary TB 
occurring together with an RTI or in isolation. Studies have demonstrated that TB can be 
missed where it occurs together with an RTI in young children
10-12
.This is partly because the 
symptoms and signs of the two conditions overlap, and because making a definitive diagnosis 
of pulmonary TB in young children is not always possible. Only a few cases of pulmonary 
TB in young children are bacteriologically confirmed since the disease is paucibacillary and 
specimen collection difficult in this age group. The possibility of undetected TB raises the 
likelihood of detection bias in TB vaccine trials. This would underestimate the burden of TB 
disease (the trial endpoint) and inflate vaccine efficacy. This highlights the need for improved 
diagnostics for pulmonary TB in this age group. 
 
Nearly 10% (7% in Cohort 1 and 11% in Cohort 2) of all admissions occurred in children less 
than 1 month old even though both studies only enrolled healthy children. This demonstrates 
the general morbidity burden that vaccine trials enrolling neonates in similar settings are 
likely to face. Mortality in the first month of life was higher in Cohort 1 were infants were 






















In both cohorts, a significant proportion of deaths could not be assigned to specific causes of 
death, despite attempts to review clinical records including death certificates and information 
from verbal autopsy interviews. This is significant since it could not be determined if any of 
the deaths were due to TB. Unknown causes of deaths among trial participants in TB vaccine 
trials would impact on the assessment of vaccine safety and efficacy. This highlights a need 
for close follow-up of all trial participants and an investigation of other approaches for the 





The overall morbidity and mortality profile was the same over the eight year period during 
which these studies were conducted. This was against a background of largely unchanged 
health policies in the area. The introduction of the vaccines against rotavirus and 
Streptococcus pneumoniae important causative agents of diarrhoea and pneumonia in young 
children in South Africa occurred after both studies had completed enrolment and follow-up 
25
. Therefore the burden of morbidity and mortality due to RTIs and diarrhoeal disease at this 
site is likely to be different in future studies. However, similar profiles would be expected for 
other conditions and in trials that are conducted in similar settings. 
 
The reason for a significantly higher proportion of admissions for unknown or unspecified 
conditions in Cohort 2 is not entirely clear, given that there was no difference in the 
participants enrolled in both cohorts. A possible explanation could be that participants in the 
three monthly home visits group in Cohort 2 had a high probability of being referred to 
healthcare centres on the basis of unclear or very mild symptoms of illness. A further 
explanation could relate to delays or difficulties in obtaining clinical records of children in 
the less intensive case finding group in Cohort 2 resulting in the reasons for these admissions 
being categorised as unknown or unspecified. This is consistent with the data on causes of 
mortality. 
 
This analysis had several limitations. Diagnoses were based on record review, and could have 
been incorrect for some cases given the limitations associated with record review namely 

















are consistent with the regional and national childhood mortality profile suggesting that any 
error is insignificant. Data on disease severity were not recorded; therefore it is not possible 
to comment on disease severity in these cohorts. Thirdly only data on the main diagnosis or 
condition at admission were analysed, hence we cannot report on comorbidities an important 




Serious adverse events in these TB vaccine trials were dominated by RTIs and diarrhoeal 
disease. Hospital admissions and deaths due to TB were significant contributors to the 
morbidity and mortality burden in these trials, even though their overall proportions were 
low. Specific causes of mortality could not be determined for a significant proportion of 
deaths. Despite extensive follow-up and data collection the ability to detect TB among trial 
participants who are hospitalised and those who may die is limited by the unavailability of 
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Chapter 7: Discussion and General Conclusions 
 
 
Despite the recent decline in the global tuberculosis (TB) incidence and mortality, the burden 
of the disease still remains high with an estimated 8.7 million incident cases (range, 8.3 
million–9.0 million) globally reported in 2011 
1
. It is therefore recognised that a multi-
pronged approach that includes the development of novel drugs, rapid and more effective 
diagnostics, and an effective vaccine is needed to accelerate the decline of TB cases 





While significant progress has been made in the development and testing of new TB 
vaccines, the conduct of clinical trials of new TB vaccines is still beset by challenges 
2, 3
. A 
major challenge is the absence of a correlate or surrogate endpoint of protective immunity 
against TB 
4-6
. Therefore the success of new TB vaccines cannot be easily predicted or 
identified in experimental animal models or early phase clinical trials. Efficacy can only be 
evaluated against a clinical endpoint: the development of TB disease 
4, 7-10
. However, in 
infants and young children, who have been identified as a target group for new TB vaccines 
the detection and diagnosis of TB disease can be difficult. The signs and symptoms are non-
specific, overlap with those of other childhood conditions, and there is a low rate of 
bacteriological disease confirmation
 11-15
. Howbeit, the accurate determination of vaccine 
safety and efficacy rests on the detection of all TB suspects and subsequently all TB cases 
among trial participants in a TB vaccine trial. Inaccurate and incomplete detection of suspects 
and cases can result in the “dilution” and poor precision of vaccine efficacy measurements
 16, 
17
. Therefore TB case-finding is important in the conduct of TB vaccine trials. 
 
Studies in adults have shown that active case-finding (ACF) for TB yields more TB cases 
than passive case-finding (PCF) 
18
. However few studies have investigated ACF strategies in 
children. ACF strategies that have been tested in adults include door-to-door household visits, 
enhanced case-finding (ECF), out-patient screening, mass radiographic screening and contact 
tracing. Most of these strategies rely on the detection TB through the collection of spot 
sputum specimens for microbiological examination, or on the spot radiographic examination, 
or symptom assessment. Differences in adult and childhood TB restrict the direct application 
of these strategies to children. Young children cannot produce spot sputum specimens for 

















difficult, and symptoms of TB in children overlap with those of other childhood conditions 
11, 
19
. Contact tracing which has been successful in detecting TB in adults and children in low 
TB burden countries 
20, 21
, is not suited for the detection of cases in infant TB vaccine trials. 
This is because it relies on the detection of adult TB cases, and yet, adult cases especially in 
high TB burden settings do not always present to healthcare centres, and even when they do 
so, TB may not be correctly diagnosed 
22, 23
. The child cases would therefore remain 
undetected.  
 
There has therefore limited evidence to guide the selection of ACF strategies for clinical trials 
of new TB vaccines conducted in young children. This thesis has explored ACF in young 
children in a high TB burden setting with the aim of informing case-finding for clinical trials 
of TB vaccines conducted in this population in similar settings. 
 
 
TB case yield from two ACF strategies in young children: Recommendations for ACF in 
infant TB vaccine trials 
We compared two ACF strategies and have shown that a more intensive strategy that 
incorporates regular home visits maximises case detection, yielding more cases than a record 
surveillance system that only includes a study close-out visit 
9
. Given the challenges of 
diagnosing pulmonary TB in young children it is possible that some of the TB cases detected 
by the more intensive strategy may have only exhibited transient features associated with 
recent infection with M.tb, and therefore may not have been “true” cases. However, such 
cases are significant since “transient primary TB reflects the desirable immune containment 




. Therefore intensive 
case-finding incorporating regular contact for symptom based screening maximizes case 
detection and is recommended for clinical trials of new TB vaccines conducted in young 
children in high TB prevalence settings.  
 
In both strategies the number of TB cases detected was low (89 and 36 cases of definite and 
probable TB in the more and less intensive groups respectively (Chapter 3)), and only a few 
cases were bacteriologically confirmed. This demonstrates that in the absence of biomarkers 
of protective immunity against TB, clinical trials of new TB vaccines in young children 

















include clinically based case definitions 
4-6
. Significant progress has been made in developing 
standardized and objective clinically based case definitions for pulmonary TB in young 





TB incidence by age in children less than 5 years old: Duration of subject follow-up in 
infant TB vaccine trials 
Our analysis of age related incidence of TB in children under the age of 5 years, showed the 
incidence of TB peaking in the 12-23 month age category with high rates persisting beyond 
24 months 
25
. Given the relatively low case yield over a two year period as was shown in our 
ACF study, these findings suggest that extending participant follow-up time beyond 24 
months could improve case accrual.  
 
 
Comparison of the Tuberculin skin test and the QuantiFERON-TB-Gold–In-Tube 
assay: Detection of M.tb infection in young children with pulmonary TB  
Our comparison of the tuberculin skin test (TST) and QuantiFERON-TB-Gold–In-Tube assay 
(QFT) among TB suspects showed equivalent performance of the two tests in detecting M.tb 
infection among young children with suspected TB disease in our setting
 26
. Although 
interferon release assays have higher specificity for M.tb infection, given the logistical 
requirements for these assays (consumables, phlebotomy, adherence to strict times frames for 
laboratory processing), and the overall costs of conducting TB vaccine trials, our findings 
suggest that the TST remains a feasible and useful test to aid the diagnosis of TB disease (by 
detecting M.tb infection) when administered, read and interpreted appropriately. Our data 
supports the inclusion of the TST in the proposed case definitions for intrathoracic TB 
7, 8
. A 
recent systematic review has also shown no difference in sensitivity of the TST and IGRAs 
for M.tb, while specificity was higher for the IGRAs 
27
. Molecular tests with greater 
sensitivity and specificity for TB disease are ideal for TB vaccine settings as they increase 
diagnostic certainty 
28-30
. (This work was done before these tests were available hence they 
were not evaluated in this setting). 
 
 
Chest radiographic findings in ACF in young children:-Radiologic evidence of TB 

















Chest radiographs (CXRs) remain an integral part of diagnosing TB in children 
7, 8, 31, 32
. ACF 
in young children in a high TB burden setting detected uncomplicated primary complex TB 
with a small proportion of uncontained parenchymal disease. This mild radiographic disease 
phenotype may reflect radiological changes associated only with M.tb infection, and not TB 
disease. Growth failure appears to be the clinical hallmark of uncontained pulmonary TB in 
young children in this setting. Therefore, infant TB vaccine trials, adopting ACF should 
prioritize growth failure as a sentinel clinical feature for early detection of childhood TB in 
high burden settings. 
 
Given the high inter observer variation in the interpretation of CXR findings 
19
, and the 
pivotal role of chest radiographs in the diagnosis of childhood TB, there is a need to 
standardize the reading and recording of CXR findings in TB vaccine trials and other 
research settings. In this regard, in 2010, a workshop to review and discuss the reading, 
interpretation and recording of paediatric CXR findings in infant TB vaccine trials was held 
at the University of Cape Town. The workshop brought together expert TB paediatricians, 
radiologists and clinicians from four TB vaccine trial sites in Africa (South Africa, Kenya, 
Uganda and Mozambique). A chest radiograph reading and recording form (Appendix 2) was 
developed as an output of this workshop. This form was used in the work presented in this 
thesis, and has now been proposed as one approach to ensure accurate and standardized 
reading and recording of CXR findings in young children in research settings 
7
. There is 
however need for continual review of the harmonisation of CXR reading, interpretation and 
recording in TB vaccine trial sites. 
 
 
Hospital admissions and mortality among TB vaccine trial participants: Detecting TB 
morbidity and mortality in infant TB vaccine trials 
Our analysis of morbidity and mortality data from two TB vaccine trials showed a profile 
dominated by respiratory tract infections (RTIs) and diarrhoeal disease. Hospital admissions 
and deaths due to TB were significant contributors to the morbidity and mortality burden in 
these trials, even though their overall proportions were low. Up to 10% of participants were 
hospitalised for unknown or unspecified conditions, and up to 51% of deaths were due to 
unknown and unspecified conditions. Both these findings have a major impact on the 

















cases had TB disease. Autopsies could add value in detecting cases of TB in vaccine trials 
where the proportion of unknown causes of mortality and that attributed to RTIs is high, as 
was found in our studies. Targeted post mortem biopsies have previously been conducted to 
investigate the presence TB in human immunodeficiency virus (HIV) infected individuals 
33, 
34
. However in many TB endemic countries the subject of autopsies is likely to be restricted 
by cultural, ethical and logistical reasons, as was found during community dialogues at the 
SATVI trial site. Our findings also demonstrate that the absence of better diagnostic tools for 
childhood TB limits the detection of cases among TB vaccine trial participants. 
 
 
Relevance for TB control programmes 
These findings from this thesis are also relevant for TB control programmes. We have shown 
that ACF beyond contact tracing can be beneficial in children. As in adults, disease is also 
detected at an earlier stage and is therefore mild. This minimizes the occurrence of severe and 
disseminated forms of TB which were very limited in our studies. In our ACF study, 18% of 
cases were detected through hospitalisation and health facility radiology department lists
9
. 
This demonstrates that a significant proportion of child TB suspects present to healthcare 
centres. A previous study showed a high prevalence of TB in hospitalised children 
35
. Data 
have however indicated limited knowledge and skills in the diagnosis and management of 
childhood TB among healthcare workers 
36, 37
. Therefore children with TB who present to 
health facilities may not be correctly diagnosed. Thus there is need to build, improve, and 
strengthen the capacity of clinic and hospital staff to diagnose TB in children since cases can 
easily be missed due to an clear pathopneumonic presentation in this age group, and overlap 




In the absence of biomarkers of protective immunity against TB and in the absence of 
improved TB diagnostics, future studies should determine the costs of the different ACF 
strategies in children in TB vaccine trial settings and in programmatic settings. In addition 
efforts should also be made to monitor the harmonization of TB case definitions for research 
settings including the reading and interpretation of CXR findings in TB vaccine trial sites. 

















of subjectivity and are therefore prone to a margin of error is a significant challenge in the 
conduct of TB vaccine trials in children and in the determination of the efficacy of these 
vaccines. Further work in the area of TB vaccine trials in infants should also continue to 
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Appendix 1: Hospital admission morbidity profile (Cohort 1 and Cohort 2) 
 
Supplementary Table: Hospital admission morbidity profile: Cohort 1 and Cohort 2 
  Cohort 1 N= 2895 Cohort 2 
 
N=718 p value 
Diagnosis n % n %   
Respiratory tract infections (infections of the upper and 
lower respiratory tract), excludes pulmonary tuberculosis 954 33.0 223 31.1 0.33 
Diarrhoeal disease (includes the term gastroenteritis, and 
diarrhoea and vomiting) 926 32.0 175 24.4 0.0001*  
TB ( pulmonary tuberculosis) 128 4.4 45 6.3 0.03* 
Malnutrition ( includes marasmus and kwashiorkor) 88 3.0 11 1.5 0.03* 
Jaundice 60 2.1 16 2.2 0.87 
Meningitis  ( viral, bacterial, unspecified, includes 
tuberculous meningitis 53 1.8 9 1.3 0.35 
Perinatal conditions  and  prematurity 49 1.7 7 1.0 0.18 
Convulsions (includes,  epilepsy) 49 1.7 6 0.8 0.08* 
Injuries  (includes  fractures, head injuries  and   injuries 
due to motor vehicle accidents 47 1.6 18 2.5 0.10 
Febrile convulsions and  pyrexia if unknown origin 40 1.4 12.0 1.7 05 
Renal conditions ( includes infections) 35 1.2 6 0.8 0.36 
Wheezing (unspecified) 35 1.2 0 0.0   
Burns ( hot water and fire burns) 33 1.1 6 0.8 0.48 
HIV related illnesses (included cases with  confirmed HIV 
infection) 32 1.1 6 0.8 048 
Congenital conditions  31 1.1  0  0.00   
Otitis media 32 1.1 7 1.0 0.82 
Sepsis (generalised bacterial infection including 
meningococcemia) 31 1.1 3 0.4 0.09 
Poisoning ( ingestion of hazardous material such  including 
paraffin) 30 1.0 10 1.4 0.35 
Abscess(includes  cellulitis  and empyema) 25 0.9 8 1.1 0.62 
Dermatological conditions 20 0.7 6 0.8 0.78 
Minor surgical procedures  (includes circumcision) 15 0.5 10 1.4 0.01* 
Asthma  10 0.3 16 2.2 <0.001* 
Eye conditions ( includes infections) 9 0.3 3 0.4 067 
Other (  condition or symptoms and signs not included in 
the conditions above) 51 1.8 36 5.0 <0.001* 




















Appendix 2: Chest radiograph reading and recording form 
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'~.~-----------------------------------------------
INFORMATION: 
• Reader code: • Study code: 
• Patient code: .............................. . • Date of read: ..................................... . 
Instructions to tick-sheet: 
A] Mark only one of the tick boxes for each image: ~s, ~, ~aybe, or ~t visible 
(Record only the most positive grading under each section. That means if there is one 
'definite' node and 3 'possible' nodes, you must tick 'yes' and nol 'maybe') 
B Please also cross an number of locations of disease on the a ro nate circled number 
Airway compressed and 
tracheal displacement 
~odular 1= Miliary or larger 
widespread and bilateral 
T8 Decision Dlymph_~y 
or Miliary = Yes 




but positive = Maybe 
Grading: D 
Yes = positive 
Maybe 
No = negative 
Post process : 
Overa ll 
Overall 
DBadq","~ = 
Unreadable 
